Science

A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects

ScienceA Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects

Abstract

Background: Several neurobiological mechanisms have been proposed to support the hypothesis of a higher COVID-19 risk in individuals with autism spectrum disorder (ASD). However, no real-world data are available on this population. Methods: We compared the period prevalence (March-May 2020) and symptom presentation of COVID-19 infections between a sample of individuals with severe ASD (n = 36) and the staff personnel (n = 35) of two specialized centers. Anti-SARS-Cov-2 antibody positivity was used as a proxy of infection. Additionally, we evaluated vaccine side effects in the same groups. Results: No significant difference was found between the prevalence of COVID-19 positivity between autistic participants and staff personnel. Levels of antibodies against the spike protein and the receptor binding domain were not significantly different between autistic and staff participants. The level of antibodies against the N-terminal domain were higher in autistic individuals. There was a significant difference between the prevalence of symptomatic COVID-19 in autistic participants (9.1%) compared to staff personnel (92.3%). The most frequent side effect among autistic participants was light fever.

Conclusions: The present study provides preliminary data on COVID-19 transmission and presentation in ASD. Our data do not support the hypothesis of a higher susceptibility and severity of COVID-19 in people with ASD.


Safeminds: Infant Gut Microbiome and Fear Response

Brain gut cartoon
https://cen.acs.org/biological-chemistry/microbiome/gut-might-modify-mind/97/i14

Note: Could the gut be the culprit behind the struggles of the young generation, riddled with anxiety, worry, and self-doubt? We know the role it plays in autistic behavior. And a certain doctor tried to ask hard questions a couple of decades ago, as you  may recall.....

###

Infant Gut Microbiome May Contribute to Fear Response Trajectory
Study Examines Microbiome Content for 1-Month and 1-Year Old Infants

The microbiome is the collection of trillions of microorganisms that colonize the digestive tract. Each person has a completely unique microbiome, made up of a network of microbiota originally determined by their DNA.

The microbiome is the collection of trillions of microorganisms that colonize the digestive tract. Each person has a completely unique microbiome, made up of a network of microbiota originally determined by their DNA. The microbiome develops rapidly during the first year of life. Previous research has linked human behaviors, including fear and anxiety, to the composition of the microbiome. It was due to these reasons that a research team from Michigan State University set out to study the emergence of fear responses in infants around 12-months old and examine if fear behavior is influenced by the development and composition of the microbiome. The Michigan State researchers theorized that there are critical windows in the development of the brain and nervous system in which variations in microbiome composition could impact infants’ fear behaviors and perhaps influence the physical structure of brain areas involved in generating fear. By recruiting a group of 34 infants, the study’s authors assessed microbiome contents and the volume of key brain regions at ages 1-month and 12-months. At the second assessment point, they also examined social and non-social types of fear behaviors in the infants. The study’s results indicated that the composition of the microbiome at 1-year “is significantly associated with increased fear behavior” and that differences in microbial colonization causes differences in fear. The researchers based these findings on a task designed to measure non-social fear. They also discovered that certain qualities of the 1-month microbiome were additionally associated with increased non-social fear at 1-year. Additionally, this study demonstrated a “suggestive” relation between contents of the infant microbiome and volumes of the amygdala and the prefrontal cortex. Despite finding associations between microbiome and variations between individual fear responses among the infants, the study’s authors say it is too early to label any specific microbiome contents as good or bad. This is mostly due to differences among individuals and also because some microbes may have positive and negative impacts in different contexts.


US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity” J. Bart Classen, MD*

New paper

FDA are expected to vote today to fully license the Pfizer vaccine while hiding the hideous fallout

https://www.scivisionpub.com/pdfs/us-covid19-vaccines-proven-to-cause-more-harm-than-good-based-on-pivotal-clinical-trial-data-analyzed-using-the-proper-scientific--1811.pdf


ABSTRACT

Three COVID-19 vaccines in the US have been released for sale by the FDA under Emergency Use Authorization (EUA) based on a clinical trial design employing a surrogate primary endpoint for health, severe infections with COVID-19. This clinical trial design has been proven dangerously misleading. Many fields of medicine, oncology for example, have abandoned the use of disease specific endpoints for the primary endpoint of pivotal clinical trials (cancer deaths for example) and have adopted “all cause mortality or morbidity” as the proper scientific endpoint of a clinical trial. Pivotal clinical trial data from the 3 marketed COVID-19 vaccines was reanalyzed using “all cause severe morbidity", a scientific measure of health, as the primary endpoint. “All cause severe morbidity” in the treatment group and control group was calculated by adding all severe events reported in the clinical trials. Severe events included both severe infections with COVID-19 and all other severe adverse events in the treatment arm and control arm respectively. This analysis gives reduction in severe COVID-19 infections the same weight as adverse events of equivalent severity. Results prove that none of the vaccines provide a health benefit and all pivotal trials show a statically significant increase in “all cause severe morbidity" in the vaccinated group compared to the placebo group. The Moderna immunized group suffered 3,042 more severe events than the control group (p=0.00001). The Pfizer data was grossly incomplete but data provided showed the vaccination group suffered 90 more severe events than the control group (p=0.000014), when only including “unsolicited” adverse events. The Janssen immunized group suffered 264 more severe events than the control group (p=0.00001). These findings contrast the manufacturers’ inappropriate surrogate endpoints: Janssen claims that their vaccine prevents 6 cases of severe COVD-19 requiring medical attention out of 19,630 immunized; Pfizer claims their vaccine prevents 8 cases of severe COVID-19 out of 21,720 immunized; Moderna claims its vaccine prevents 30 cases of severe COVID-19 out of 15,210 immunized. Based on this data it is all but a certainty that mass COVID-19 immunization is hurting the health of the population in general. Scientific principles dictate that the mass immunization with COVID-19 vaccines must be halted immediately because we face a looming vaccine induced public health catastrophe.


Nothing to see here! 60% of deaths are Covid vaccines on 30 year-old database

Nothing to see here42% of reports and 60% of fatal reports to VAERS (started in 1990) are for Covid products since December: fatal vaccine reports to Yellow Cards are more than 20,000% up on the year

By John Stone

This is a brief investigation into the public data as it stands in mid August 2021. I would add that the point is not that this is the highest quality data but that it is the only data there is - we are being deliberately deprived of real data through negligence at best, as the FDA confessed to the New York Times early on. They had not got the machinery running - or more likely  they had it running and were just were not telling us about it. And so we get back  to VAERS which was diagnosed in 2010 as being so deficient it was picking up less than 1% of events (at which point US government agencies evidently realised that they were on to a good thing and decided not to streamline it). So here are two relative measurements.

42% of all reports to VAERS from 1990 to August 13, 2021 are for Covid vaccines (595,662/1,409,664)

60% of all reports to VAERS “where patient died” from 1990 to August 13, 2021 are for Covid vaccines (13,068/21,936)

I am not saying that we should just multiply these figures simplistically by 100 but they are indicative that there is something drastically amiss.

Meanwhile, we have a different collection of data from the United Kingdom to August 11. Here we should bear in mind that the population of the UK is one fifth of the US and the licensing body, the MHRA, generally reckons that reports represent about 10% of cases.

To date there have been 347,032 Yellow Cards, 1,151,768 Adverse Events, 1,596 Fatal 

This breaks down as follows:

Pfizer 36.6m doses 104,446 (1 Yellow Card in 350) 293,779 Adverse Events (2.8 per card) 501 Fatalites (1 in 73,054)

Astra Zeneca 48.6m doses 228,239 Yellow Cards  (1 in 213) 813,622 Adverse Events (3.6 per card) 1,053 Fatalities (1 in 46,154)

Moderna 2m doses 13,325 Yellow Cards (1 in 150) 41,274 Adverse Events (3 per card) 14 Fatalities (1 in 142,857)

Brand unspecified 1,022  Yellow Cards 3,093 Adverse Events 28 Fatalities

The fact that three brands have such distinct adverse event profiles argues strongly against this being background noise, however there are overwhelming reasons why most reports would never get made: people will not report because they don’t know to, because they don’t know how to, because the ethos is overwhelmingly hostile and they think it is the wrong thing to do or they are scared, or because they are too sick or even dead. By comparison the average number of vaccine reports for the previous ten years was 3,039 with 8 fatalities: 200 times the fatalities and we are not a year in: off the scale and the world is run by madmen.


Subscribe to Professor Exley's Aluminium Research Group Site

AluminumOver the last few years, and certainly since the COVID lockdown in 2020, we've discussed how we will communicate if and when we are "shut down" whether by social media or web platforms, or even our employers. When AofA was launched 14 years ago, one of our main focuses was on mercury. Since that time, aluminum has become a topic of grave concern, due in large part to the work of Professor Christopher Exley, whose tenure at Keele University in the UK will be coming to a close at the end of August.

Professor Exley is creating a website where you can continue to follow and support his important work. We invite you to click in and SUBSCRIBE to updates.

Welcome to the Aluminium Research Group

Are you interested in keeping in touch with our research? If so, please feel free to subscribe to our mailing list here, thank you: Subscribe

The Birchall Centre

Welcome to the website of the Aluminium Research Group. The group was previously based in The Birchall Centre, Keele University from 1992 to 2021. We are currently looking for a new home. In the meantime we have set up this website to keep as many as possible informed about our research and research activities.

Our Research

The Unit started off with three general themes, of which our group focus is Aluminium and Silicon in Biology. The group is led by Professor Christopher Exley, FRSB and the current research themes within the group are varied, including metals and amyloids; biosilicification in plant species; human exposure to Aluminium, whether intentional (e.g. in antiperspirants or adjuvants) or unintentional; and hydroxyaluminosilicates.

 


Autism Tsunami: the Impact of Rising Prevalence on the Societal Cost of Autism in the United States

Breaking newsCongratulations to authors Mark Blaxill (Age of Autism Editor-At-Large), Toby Rogers and Cynthia Nevison.

Blaxill, M., Rogers, T. & Nevison, C. Autism Tsunami: the Impact of Rising Prevalence on the Societal Cost of Autism in the United States. J Autism Dev Disord (2021). https://doi.org/10.1007/s10803-021-05120-7

Abstract

The cost of ASD in the U.S. is estimated using a forecast model that for the first time accounts for the true historical increase in ASD. Model inputs include ASD prevalence, census population projections, six cost categories, ten age brackets, inflation projections, and three future prevalence scenarios. Future ASD costs increase dramatically: total base-case costs of $223 (175–271) billion/year are estimated in 2020; $589 billion/year in 2030, $1.36 trillion/year in 2040, and $5.54 (4.29–6.78) trillion/year by 2060, with substantial potential savings through ASD prevention. Rising prevalence, the shift from child to adult-dominated costs, the transfer of costs from parents onto government, and the soaring total costs raise pressing policy questions and demand an urgent focus on prevention strategies. Read here: https://doi.org/10.1007/s10803-021-05120-7

The Journal of Autism and Developmental Disorders is the leading peer-reviewed, scholarly periodical focusing on all aspects of autism spectrum disorders and related developmental disabilities.

Continue reading "Autism Tsunami: the Impact of Rising Prevalence on the Societal Cost of Autism in the United States" »


Safeminds Reports Contradicting Study on Maternal Smoking and Autism

Doctors smokeThank you to Safeminds for updating the community with new science. Science is rarely settled.

New Study Contradicts Last Month’s Study Showing an Association

Citing that research on in utero exposure to maternal environmental tobacco smoke (ETS) or active maternal smoking and the development of autism spectrum disorder (ASD) has been inconsistent, researchers from the California Department of Public Health set out to examine in utero cotinine concentrations as a tobacco exposure measurement. The results of their new study was recently published in Autism Research, the official journal of the International Society of Autism Research (INSAR). In order to conduct this research, the study’s authors measured cotinine levels in blood samples of women in their second trimesters.  A total of 498 ASD cases and 499 controls born in California during 2011-2012 were accessed for this investigation. The research team also obtained self-reported maternal cigarette smoking habits during and immediately prior to pregnancy as well as other pertinent information from birth records.  After running the data on the mother’s cotinine concentrations, the researchers found no association between in utero exposure to tobacco smoke from maternal ETS exposure or from active smoking and ASD. This finding contradicts a study from a few weeks ago which reported that heavy smoking during pregnancy was linked to autism in offspring. Last month’s study came to their conclusion by connecting California birth records to cases of autism maintained by the California Department of Developmental Services. However, this new study is the first to measure cotinine in mother’s blood during pregnancy and then study the chemical’s association with the development of autism in offspring. The March of Dimes, an organization dedicated to fighting for the health of all pregnant mothers and babies, produces a list of dozens of health risks for infants born to mothers who smoke. Interestingly, autism is not included on their list which reinforces the conclusion of this new study and also adds more evidence that maternal smoking during pregnancy is not fueling the autism epidemic.

Study Abstract


The Aluminium Content of Infant Vaccines Is Akin To A Lottery

The Lottery cover
Shirley Jackson's story exposed the willingness of townfolk to harm others to protect themselves as if a ritual.

Below is a link to Professor Chris Exley et al research. Exley is a Professor in Bioinorganic Chemistry in the Aluminium and Silicon Research Group at The Birchall Centre, Lennard-Jones Laboratories, at the UKs'sKeele University and a preeminent expert in aluminum toxicity.

While the world revolves around COVID as if it is the sun, moon and stars, there is a universe of danger that honorable scientists are still studying. Thank God. Professor Exley, of course, has been censored and punished for his work. 

Vaccine manufacturers are not held to any gold standard. You can have more faith in the number of crisps in a bag than the toxic metals in vaccines mandated for children.

###

The measurement and full statistical analysis including Bayesian methods of the aluminium content of infant vaccines

Abstract

Background

Aluminium salts are the most common adjuvants in infant vaccines. The aluminium content of a vaccine is provided by the manufacturer and is indicated on the patient information leaflet. There is no independent verification, for example by the European Medicines Agency, of the aluminium content of infant vaccines.

Methods

We have measured the aluminium content of thirteen infant vaccines using microwave-assisted acid and peroxide digestion followed by transversely heated graphite furnace atomic absorption spectrometry. Our data are compared with manufacturer’s data using full statistical analyses including Bayesian methods.

Results

We found that only three vaccines contained the amount of aluminium indicated by the manufacturer. Six vaccines contained a statistically significant (P < 0.05) greater quantity while four vaccines contained a statistically significant (P < 0.05) lower quantity. The range of content for any single vaccine varied considerably, for example, from 0.172 to 0.602 mg/vaccine for Havrix.

Conclusions

The data have raised specific questions about the significance of the aluminium content of vaccines and identified areas of extremely limited information. Since aluminium is a known toxin in humans and specifically a neurotoxin, its content in vaccines should be accurate and independently monitored to ensure both efficacy and safety.


Deregulating GM: Obscene Farce of the Modern British State

image from upload.wikimedia.orgBy John Stone
 
This is a succinct response to the British government consultation on the future of GMO technology taking place amid zero publicity and about to close (last day for submissions Wednesday). Note also the valuable introduction at Alliance for Natural Health.
 
Response to consultation ‘The regulation of genetic technologies’

This document is couched in up-side down language which some might term Orwellian:

1) It is actually about the deregulation of genetic technologies

2) It represents this as a “green” policy when it is patently an opportunistic attack by an industrial lobby on our natural environment, and upon bio-diversity. It could not be more anti-green in any way that could normally or traditionally be understood

3) Previous moves of this kind globally have left small and medium landholders at the mercy of grasping, unscrupulous manufacturers

4) If part of the argument is that the putative advances could also be achieved without GM technology, why do we need GM at all? This is not a credible explanation for changing the law

5) If GM is deregulated the only people the manufacturers will be answerable to is their shareholders, so how is the public interest represented?

6) I tried taking the survey but found it full of leading questions

It is shocking that this matter is not being raised in an openly democratic manner. While the British public have always rejected GM produce to the extent that it is presently unsaleable in our country, deregulating it was never conspicuously brought up as a reason for leaving the European Union at the time of Referendum in 2016 or at the December 2019 General Election: the only time I recall this project being mentioned was the Prime Minister’s speech on entering Downing Street in July 2019. This is a radical departure for the UK but the public are being cynically kept out of the picture - although there is the present consultation you will not read or hear about it in the mainstream media. One can deduce that the reason for this is that if it was adequately reported it would be overwhelmingly unpopular.

The slogan ‘Building back greener’ used in the document derives from the World Economic Forum who are also putting it out that in ten years-time no one but a tiny global elite will own anything but “will be happy”. If the government is dancing to the tune of the Great Reset perhaps it should tell the public who elected it where it is heading because no one could have imagined little more than a year ago what they were voting for. So much for Margaret Thatcher's “property-owning democracy” recently reiterated by the Prime Minister while apparently hooked into an alternative, techno-feudalist, ideology. What now are we to believe either about the environment, safe food, property or democracy?

John Stone, UK Editor, Age of Autism


Science Has Never Been Settled

Question authorityI saw this video on Facebook yesterday, and could not help but draw a bead from ancient Rome and modern Western medicine. Medicine has always fought new science when it challenged their dearly held beliefs.  Few groups know this better than the biomedical and vaccine injury autism community.  Vesalius had to combat some 1300 years of Galen of Pergamon's work, which was considered the gold standard of scientific belief. But the video is just 5 minutes long.

###

From TedEd: Learn about the Greek physician and philosopher Galen of Pergamon, whose experiments and discoveries changed medicine. -- In the 16th century, an anatomist named Andreas Vesalius made a shocking discovery: the most famous human anatomy texts in the world were wrong. While Vesalius knew he was right, announcing the errors would mean challenging Galen of Pergamon. Who was this towering figure? And why was he still revered and feared 1,300 years later? Ramon Glazov profiles the most renowned physician in medical history. Lesson by Ramon Glazov, directed by Anton Bogaty.


Dr. James Lyons-Weiler: Public Health Has a Plan B

Plan BJames Lyons-Weiler, PhD

1/5/2021

AS ONE WHO UNDERSTANDS complex dynamic systems, and is admittedly puzzled by the death of bioethics in the United States over the last decade, and as one with first-hand direct experience witnessing the pressures placed on biomedical researchers that place bottom-line concerns over health outcomes, in honor of those individuals in medicine and public health who have stayed the course and not sold out, I am pleased to propose a new approach to Public Health in one of my two latest peer-reviewed publications. It is a blueprint for reason-based, reality-based public health and a return to the public good model of medical practice.

Due to suppression, please share this across diverse social media platforms and by email. Take it to those who say they represent you. We must succeed.

Lyons-Weiler, J. 2020. Plan B Public Health Infrastructure and Operations
Oversight Reform for America. Intl J Vacc Theor, Pract, Research 1(2):283-294.

Click here to read Lyons-Weiler, J. 2020. Plan B Public Health Infrastructure and Operations Oversight Reform for America. Intl J Vacc Theor, Pract, Research 1(2):283-294.


UK Faces Food Shortages As A Result Of Conflicted Government Science

 image from www.gavi.orgBy John Stone

European countries have been shutting down their borders with the United Kingdom following advice that it harbours a 70% more contagious version of the Covid virus, which has already led to the new Tier 4 lockdown arrangements in Southern England and the effective cancellation of Christmas. Whether the mutation is actually more contagious is a matter for dispute between two Oxford professors. The case that the “strain” is more contagious has been hypothesised by the Nervtag advisory committee led by Prof Peter Horby. According to the Daily Mail Prof Horby, who is Professor of Emerging Infectious Diseases at the Centre for Tropical Medicine and Global Health, said the figure of 70 per cent was based on 'converging data'.

“He said: 'This is including, but not limited to, the rate of change in the frequency of detection of the variant (the growth rate) and the correlation between R values and the frequency of detection of the new variant.'”

This, however, is disputed by Prof Carl Heneghan of the Centre for Evidence Based Medicine. He told the Mail:

'I've been doing this job for 25 years and I can tell you can't establish a quantifiable number in such a short time frame.' 

He added 'every expert is saying it's too early to draw such an inference'.

Professor Heneghan said there was no doubt this time of the year, the 'height of the viral season', was a difficult time for the NHS. But he said failure to put out the basis of the figures was undermining public trust.

But while the mutation is already circulating in other European countries it has led to them shutting down food supplies to the UK coincidentally or not on the very verge of Brexit. Prof Horby had previously been embroiled in controversy earlier this year over the Hydroxychloroquine trial in which inappropriately high quantities of HCQ  were given to Covid patients already in a serious condition (the trial was funded by the Wellcome Trust and the Bill and Melinda Gates Foundation). Also on the Nervtag Committee is Prof Ferguson of Imperial College whose controversial modelling led to the UK’s first lockdown in the spring. Ferguson was forced to resign from the more prominent SAGE committee after breaking lockdown rules pursuing a romantic liaison, but not apparently from Nervtag. Ferguson’s Vaccine Impact Modelling Consortium at Imperial College is also funded by the Bill and Melinda Gates Foundation as well as the global vaccine alliance, GAVI. Ferguson's group was said to have received $185 million from the Bill and Melinda Gate Foundation between 2006 and 2018.

Converging data or converging interest?


iPAK Presents Vax Unvaxxed Study with Zero ADHD

Science post imageLyons-Weiler, J.; Thomas, P. Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses Along the Axis of Vaccination. Int. J. Environ. Res. Public Health 202017, 8674. 

Open Access (No Firewall)

Abstract: https://www.mdpi.com/1660-4601/17/22/8674
HTML Version: https://www.mdpi.com/1660-4601/17/22/8674/htm
PDF Version: https://www.mdpi.com/1660-4601/17/22/8674/pdf

Link to this page: http://ipaknowledge.org/ipak-vaxxed-v-unvaxxed-study.php

We are now moving on to Phase 2 of our study, in which they will focus on the comparison of health outcomes associated with live vs. non-live vaccines, aluminum-containing vaccines vs. non-aluminum containing vaccines, as well as studying the impact of individual vaccines on specific health outcome risks.  Become an IPAK Science Hero and make the world a safer place for our children through objective science.

In this study of over 3300 patients, we found ZERO ADHD in the unvaccinated group (N=561). We found that using billed office visits was a more powerful test than the weaker odds ratio of incidence. Even after blocking for healthcare exposure/age, family history of autoimmunity, and gender, the associations of many bad health outcomes were robust. Anemia was especially prominent in the vaccinated. Here is our announcement.

The IPAK team and Dr. Paul Thomas have published the first results from the Vaxxed vs. Unvaxxed study in the study "Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses Along the Axis of Vaccination".

Continue reading "iPAK Presents Vax Unvaxxed Study with Zero ADHD" »


Adjuvants: The BBC's Fairy Dust Future

image from external-content.duckduckgo.comby John Stone

Two days ago I received at breakfast a magazine article from an outfit called BBC Future entitled Immune Respose: The Strange Ingredients Found in Vaccines by Zaria Gorvett (pictured left).That the BBC should supply such a bland and poorly informed article for the popular market is no surprise, but nevertheless my annoyance did rise at her account of the DPT affair, and I wrote to her:

Dear Ms Gorvett,

Re: Your article “Immune Response” this morning

Despite the opprobrium heaped on John Wilson the government discreetly paid out on 600 DPT cases within three years of the vaccine damage payment act of 1979. In a letter last year to BMJ (which I append)  I also pointed out the paper by Mogensen which found that mortality in DPT vaccinated infants in Guinea-Bissau (1981) was 5 times vaccinated. This is not a small matter.

I also point out that size comparison makes no sense when talking (about)  an active ingredient of a product and I forward the link to the recent article by Prof Exley “An aluminium adjuvant in a vaccine is an acute exposure to aluminium”.

It is not correct to say that there is no evidence when there is evidence and I think you ought to reconsider.

Yours sincerely,

 John Stone, UK Editor, Age of Autism

The Benefits of DPT

(BMJ Rapid Response)

Mara Kardas-Nelson [1] should also note that as result of DPT controversy and the UK Vaccine Damage Payment Act of 1979 there were 600 payments in the period 1978-81 (1978/9: 36, 1979/80: 317, 1980/1: 256) [2,3]. The rhetoric behind the legislation was that injuries were rare but this was not borne out by the record [2,3]. The act enabled the government to retrieve the reputation of the programme amid adverse publicity by acknowledging the principle of harm but no one knew how many awards there had actually been - and initially there were a lot. This would also not take account of any deaths.

According to Mogensen et al, the introduction of DPT to Guinea-Bissau in 1981 was associated with a 5 fold increase in the rate of death [4]:

"Among 3–5-month-old children, having received DTP (±OPV) was associated with a mortality hazard ratio (HR) of 5.00 (95% CI 1.53–16.3) compared with not-yet-DTP-vaccinated children. Differences in background factors did not explain the effect. The negative effect was particularly strong for children who had received DTP-only and no OPV (HR = 10.0 (2.61–38.6)). All-cause infant mortality after 3 months of age increased after the introduction of these vaccines (HR = 2.12 (1.07–4.19))."

[1] Kardas- Nelson, 'Despite high rates of vaccination, pertussis cases are on the rise. Is a new vaccination strategy needed?', BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4460 (Published 09 July 2019)

[2] Gareth Millward, 'A Disability Act? The Vaccine Damage Payments Act 1979 and the British Government’s Response to the Pertussis Vaccine Scare', Social History of Medicine, Volume 30, Issue 2, May 2017, Pages 429–447, https://doi.org/10.1093/shm/hkv140

[3] 'Annex A - Vaccine Damage Payments claims received and award statistics', https://www.whatdotheyknow.com/request/242813/response/599844/attach/3/A...

[4] Mogensen et al, 'The Introduction of Diphtheria-Tetanus-Pertussis and Oral Polio Vaccine Among Young Infants in an Urban African Community: A Natural Experiment', Ebiomedicine March 2017, https://www.ebiomedicine.com/article/S2352-3964(17)30046-4/abstract

I forgot to mention that the old DPT contained 50 micrograms of life-enhancing ethyl mercury but not receiving  an answer I decided to forward it to her editor Amanda Ruggeri (below), who describes herself on her website as  “Journalist, Photographer, Traveler,  Historian,  Adventurer”, and obviously a very exciting person. She also has not replied. image from external-content.duckduckgo.com

What I did not know at the time that I wrote to Zaria was that before writing her amusing vaccine fairy story she had interviewed Prof Exley at length on the phone. Yesterday, he wrote to her furiously:

Dear Zaria,

This not about whether one 'likes' something or not. It is about your integrity as a journalist.

You contacted me by email to ask my advice. I was happy to help and even gave you my home telephone number since you wished to talk to me personally and not simply correspond by email.

We talked for about forty minutes. I shared with you a great deal of scientific, published, information on our expertise in aluminium adjuvants used in vaccines. I made sure that you had access to all the primary published research that we talked about. I also gave you some background on adjuvants generally. You gave the impression of both being very interested in the information I gave you and also of being grateful for my time and expertise. Afterall we are, arguably, the world's leading group researching the efficacy and safety of aluminium adjuvants used in vaccines.

When we finished our conversation, you promised to send me a link to your article. You did not do this and reading your article, I can understand why.

Not only did you not mention my contribution to your article once but when opportunities arose you chose to write what can only be described as blatant lies.

For example, even though you knew that what you had written was untrue you still wrote;

There is as little as 0.2mg of aluminium in a typical vaccine dose, which is equivalent to less than the weight of a single poppy seed. There is no evidence that any of the adjuvants currently in use lead to side-effects.

Apart from being factually incorrect the comparison with a poppy seed is absurd at best.

What happened to your editor's mantra concerning BBC Future;

We believe in truth, facts, and science. We take the time to think. And we don't accept — we ask why.

I told you everything you needed to know about how much aluminium is used in vaccines. I even shared with you some of our new research in this field about to be published in the BMJ. I pointed out to you that there are serious adverse events caused by aluminium adjuvants and I also informed you as to where you could find this information, no lesser document than the patient information leaflet provided with every vaccine.

Your writing about DPT is completely false and while we did not discuss this you could have checked this information with me at any time. You clearly chose not to check your information.

I told you the story of Glenny and the 'discovery' of aluminium adjuvants.

I also made sure that you understood which aluminium salts were used as aluminium adjuvants. Instead you wrote lies again about this;

To this day, the aluminium in vaccines is always in the form of salts. These include aluminium hydroxide (commonly used as an antacid to relieve indigestion and heartburn), aluminium phosphate (often used in dental cement) and potassium aluminium sulphate, which is sometimes found in baking powder.

You decided instead to write complete scientific nonsense in your descriptions of aluminium salts used in vaccines, why is beyond me when you had access to the correct information. What were you trying to do, make the aluminium salts sound benign by comparing them wrongly to household products?

I told you that the main reason why aluminium adjuvants are effective is because they are toxic at the vaccine injection site. I spoke to you at length about this and I pointed you towards the relevant peer reviewed published scientific literature. Your reference to uric acid at this point did not come from me and has no relevance.

This article is very shoddy journalism. It seems to have been primarily informed by a Chinese scientist working on vaccines in China. As the world's leading researcher on aluminium, I have no knowledge of this scientist only that they have no expertise in aluminium adjuvants. Why you chose to only follow their advice is insulting.

If you and your editors do truly 'believe in truth, facts, and science', then I would expect a right of reply to this inaccurate and scientifically inept article. To not do so would suggest that the written lies therein have an alternative agenda.

Yours sincerely

image from i.ytimg.com

 

 

 

 

 

Professor Christopher Exley PhD FRSB

So far, at the time of writing, Prof Exley assures me he has heard neither from Zaria Gorvett or her editor Amanda Ruggeri (which is I suppose what you would expect from the modern BBC). Perhaps as their next assignment these two geniuses can set themselves to working out why Autism Spectrum Disorders have reached 7% in Belfast schools (I have had an identical figure just quoted me by personal communication for the first year in-take of a Welsh comprehensive school). All brought to you by the BBC’s responsible journalism.

Post Script

Prof Exley has now received a succession of letters from the BBC which does not make their position any more satisfactory:

Dear Professor Exley,

Thank you very much for speaking with me the other day. I am sorry that you do not like the article. I have cc'd my editors.

Best regards,

Zaria  

*

Dear Prof. Exley,

Thank you for raising your concerns with BBC Future. We’re sorry that you feel your time in the interview was wasted; we seek information from a wide range of sources, and there is no guarantee when we do interviews that any given interviewee will be quoted or mentioned in a piece.

We’ve gone through the claims you make below and remain confident in the accuracy of our reporting. Thank you again for your time.

Best,

Amanda Ruggeri

*

Dear Professor Exley,

I’m the Editorial Director for the BBC’s international news and features output.    Amanda has passed your complaint onto me.

Let me echo Amanda’s apology for the fact that you feel your time was wasted.    We speak to a lot of people in the course of our research and are grateful to anyone who gives up their time. 

The article was amended on Thursday to clarify two points:

The weight of evidence is that adjuvants do not lead to serious side-effects.

And we added detail about the link between the pertussis vaccine and encephalopathy and corrected the statement that the vaccine had been administered for decades without incident.

Best wishes,

Mary

Mary Wilkinson, Head of Editorial Content,  BBC Global News  Ltd

Of course, no one actually says sorry for their actions, and all three are guilty of deliberately misleading the public by failing to report that they had consulted him and received  information of substance (existing in the form of peer reviewed studies in respected journals)  which stood in contradiction to the claims of the published article. If they were professionally fearful of the consequences of publishing this information then it might have been better not to publish at all. Plainly none of them have the expertise to discard Prof Exley's evidence and there is no explanation of why they chose to do this except expedience.


Simon & Schuster Presents "Imagine You Are An Aluminum Atom" by Professor Christopher Exley

Imagine-you-are-an-aluminum-atom-9781510762534_lgWe are so pleased to see that publishing giant Simon & Schuster has announced Christopher Exley's book "Imagine You Are An Aluminum Atom!"  Please click here and pre-order a copy from your favorite bookseller.  If you use Amazon, consider marking Age of Autism as your SMILE charity. Thank you.

From S&S:

Join "Mr. Aluminum," a scientist who has made the study of aluminum his life's work, on a journey of discovery, reflection, and the science of aluminum.

Professor Christopher Exley is a firm believer that science is only useful when it is properly communicated. Scientific papers are difficult vehicles for the wider communication of science and thus he has always endeavored to tell the story of his scientific research as widely as possible through myriad blogs, presentations, and interviews. Through a series of easy-reading entries written for non-scientists, Exley will educate readers about his lifelong scientific passion: aluminum. In scientific circles, aluminum—in relation to human health specifically—has gone the way of the dinosaurs (though, unlike dinosaurs, there has not yet been a popular revival!). Yet aluminum is also the greatest untold story of science.

But why do we all need to know a little bit more about aluminum? Do we need a self-help guide for living in what Exley has coined "The Aluminum Age"? What is it about aluminum that makes it different? What about iron, copper, or any of the so-called "heavy metals," like mercury, cadmium, or lead? Why must we pay particular attention to aluminum? Because its bio-geochemistry, its natural history, raises two red flags immediately and simultaneously.

These two danger signals are easily missed by all of us and easily dismissed by those whose interests are conflicted by aluminum’s omnipresence in human life and consequently, are purposely blind to its danger signals. First, aluminum, in all of its myriad forms, is super abundant; it is the third most abundant element (after oxygen and silicon) of the Earth’s crust. Second, aluminum is super reactive; it is both chemically and biologically reactive. However, these two red flags identify a paradox, as the abundant and biologically reactive aluminum has no biological function either in any organism today nor in any extinct biota from the evolutionary past. This means in practical terms that when we encounter aluminum in our everyday lives, our bodies only see aluminum as an impostor, something foreign, and something for which we have not been prepared through biochemical evolution. This in turn means that all of our encounters with aluminium are adventitious, random, and chaotic. And potentially dangerous.

Imagine You Are An Aluminum Atom: Discussions With "Mr. Aluminum" examines the science of aluminum and human health and makes them understandable to all. Within the science you will find personal recollections of events, as well as opinions and reflections upon how the politics of aluminum have influenced and interfered with doing and reporting the science. It is at once both a personal recollection of Exley's life in aluminum research and a guide on the dangers of the constant exposure to aluminum we as humans face during this "Aluminum Age." It will inform, it will provide the means to question the science, and it will, if the reader is prepared to participate, answer those frequently asked questions on aluminum and human health.


Fake Placebo Meningitis Vaccine May Have Killed Healthy 28 Year Old Brazilian Covid Vaccine Volunteer

That's the headline Reuters should have written, instead of AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue.

Candy syringe pensIf you ask anyone with middle school grasp of science what is a "placebo," they will likely say, "a sugar pill."  A placebo has always meant an inert, benign substitute for the drug being tested.  How many Earthlings understand that with this Covid vaccine, the placebo is another vaccine? And in this case, it may well have killed a healthy, altruistic 28 year young man. Our sincere condolences to his grieving family. He volunteered to help others.   And what of every parent whose child needs a meningitis vaccine for school? Are they to feel comforted?

noun
noun: placebo; plural noun: placebos

a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
"his Aunt Beatrice had been kept alive on sympathy and placebos for thirty years"
a substance that has no therapeutic effect, used as a control in testing new drugs.
a measure designed merely to calm or please someone.
"pacified by the placebos of the previous year, they claimed a moral victory"

###

SAO PAULO/FRANKFURT (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.”

AstraZeneca declined to comment immediately.

A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting the person was part of the control group that was given a meningitis jab.  Read more here.


Aluminum and Neurofibrillary Tangle Co-Localization in Familial Alzheimer’s Disease and Related Neurological Disorders

AluminumAuthors: Mold, Matthew Johna; * | O’Farrell, Adamb | Morris, Benjaminb | Exley, Christophera; *

Aluminum and Neurofibrillary Tangle Co-Localization in Familial Alzheimer’s Disease and Related Neurological Disorders

Abstract

Background:

Protein misfolding disorders are frequently implicated in neurodegenerative conditions. Familial Alzheimer’s disease (fAD) is an early-onset and aggressive form of Alzheimer’s disease (AD), driven through autosomal dominant mutations in genes encoding the amyloid precursor protein and presenilins 1 and 2. The incidence of epilepsy is higher in AD patients with shared neuropathological hallmarks in both disease states, including the formation of neurofibrillary tangles. Similarly, in Parkinson’s disease, dementia onset is known to follow neurofibrillary tangle deposition.

Objective:

Human exposure to aluminum has been linked to the etiology of neurodegenerative conditions and recent studies have demonstrated a high level of co-localization between amyloid-β and aluminum in fAD. In contrast, in a donor exposed to high levels of aluminum later developing late-onset epilepsy, aluminum and neurofibrillary tangles were found to deposit independently. Herein, we sought to identify aluminum and neurofibrillary tangles in fAD, Parkinson’s disease, and epilepsy donors.

Methods:

Aluminum-specific fluorescence microscopy was used to identify aluminum in neurofibrillary tangles in human brain tissue.

Results:

Continue reading "Aluminum and Neurofibrillary Tangle Co-Localization in Familial Alzheimer’s Disease and Related Neurological Disorders " »


“The Largest Unethical Medical Experiment in Human History”

EMF warningNote: Many of our readers have taken steps to thwart wireless in their homes. However, with COVID school and work restrictions, most all of us are being forced to use wireless devices several hours every single day. It's a Zoom/Google Classroom world. There's no avoiding EMF. Dr. Kostoff,  a valued AofA reader and commenter, has written an detailed monograph that we share today. I looked up the term "monograph, and learned that it means "a detailed written study of a single specialized subject or an aspect of it." Mono - one. Graph - writing.

THE LARGEST UNETHICAL MEDICAL EXPERIMENT IN HUMAN HISTORY

Ronald N. Kostoff, Ph.D.Research Affiliate, School of Public Policy, Georgia Institute of Technology

KEYWORDS Unethical Research; Electromagnetic Fields; Wireless Radiation; Radio frequency Radiation; RF; Non-Ionizing Radiation; Mobile Networking Technology; 5G; Adverse Health Effects

ABSTRACT

This monograph describes the largest unethical medical experiment in human history: the implementation and operation of non-ionizing non-visible EMF radiation (hereafter called wireless radiation) infrastructure for communications, surveillance, weaponry, and other applications. It is unethical because it violates the key ethical medical experiment requirement for “informed consent” by the overwhelming majority of the participants.

The monograph provides background on unethical medical research/experimentation, and frames the implementation of wireless radiation within that context. The monograph then identifies a wide spectrum of adverse effects of wireless radiation as reported in the premier biomedical literature for over seven decades. Even though many of these reported adverse effects are extremely severe, the true extent of their severity has been grossly underestimated. Most of the reported laboratory experiments that produced these effects are not reflective of the real-life environment in which wireless radiation operates.

Many experiments do not include pulsing and modulation of the carrier signal, and most do not account for synergistic effects of other toxic stimuli acting in concert with the wireless radiation. These two additions greatly exacerbate the severity of the adverse effects from wireless radiation, and their neglect in current (and past) experimentation results in substantial under-estimation of the breadth and severity of adverse effects to be expected in a real-life situation. This lack of credible safety testing, combined with depriving the public of the opportunity to provide informed consent, contextualizes the wireless radiation infrastructure operation as an unethical medical experiment.  Continue reading here.


Aluminum is a Secret Sauce!

Burger foilSuch a clever headline  and a WHOPPER of an obfuscation from National Pharma Radio, aka NPR. In the article they jauntily refer to a substance called "alum...."  The author might want to check in on the work of Chris Exley in the UK. His latest? The role of aluminum adjuvants in vaccines raises issues that deserve independent, rigorous and honest science

From NPR:

The Special Sauce That Makes Some Vaccines Work

There are many approaches to making a vaccine against COVID-19. Some use genetic material from the coronavirus, some use synthetic proteins that mimic viral proteins and some use disabled versions of the virus itself.

But before any of these approaches can generate the antibodies to the coronavirus that scientists say are essential to protecting people from getting sick, the immune system has to be primed to make those antibodies.

That's the job of something called an adjuvant.

"The definition of [an] adjuvant is something you add to enhance, in the case of immunity, the immune response," says Gregory Glenn, president of research and development at Novavax, one of the companies that has received money from Operation Warp Speed.

Vaccines essentially trick the body into making an immune response to a specific virus or bacterium, so if something dangerous comes along, the immune system will be prepared.

But before it can prompt a response to a specific virus, the immune system has to be made ready.

"When you inject a vaccine, the first immune cell that's of importance is a dendritic cell," Glenn says.

Dendritic cells are part of what's called the innate immune response. These cells will respond to anything foreign that enters the body, the coronavirus included.

Continue reading "Aluminum is a Secret Sauce!" »


Interview with Prof Chris Exley on People Behind the Science

Podcast_channel_artworkFrom Professor Chris Exley:

In April 2020, I agreed to a telephone interview with Marie McNeely, the co-founder of an organisation called People Behind the Science (http://www.peoplebehindthescience.com/). The interview took place in early May 2020 to the apparent satisfaction of all concerned. In late June 2020, I received an email from Michael Green, also a co-founder of People Behind the Science, telling me, without explanation, that my interview would not be broadcast on their podcast. Subsequent emails from myself asking for an explanation and asking for the return of a copy of the interview were completely ignored by Green. Only when my US legal representatives issued a demand letter for a copy of the tape of the interview was a reply from Green forthcoming. He agreed to send an mp3 copy of the interview to prevent legal action being taken against him. However, what he actually sent was not what I asked for. He sent a highly edited copy of the interview in which there are many gaps and all words spoken by Marie McNeely had been removed. This is the low-resolution interview tape that I received from Green. Perhaps, as you listen you can play, fill in the gaps? Make your own judgement as to whether anything I say on this version of the interview would warrant censorship. Rather it appears to me from everything that has gone on that I am the subject of censorship here and that someone has threatened Green and McNeely with some form of repercussion should they broadcast my interview on their podcast. Whatever the reason, People Behind the Science and specifically McNeely and Green, should be ashamed of their actions. They do not deserve the support of anyone listening to or contributing to their podcast in the future.

 


SafeMinds: Having an Aunt or Uncle with Autism May Put Children at Higher Risk of ASD

Safeminds 2018 logoRisk estimated at 3 to 5 percent vs. 1.5 percent in general population

According to new research from the National Institutes of Health (NIH), a child who has a parent with a sibling on the spectrum is more likely to be diagnosed with autism spectrum disorder (ASD) compared to the general population. The study, published in Biological Psychiatry, analyzed health records of approximately 850,000 children born in Sweden between 2003-2012. Using the Swedish National Patient Register and the Multi-Generation Register, information on ASD diagnoses in both the child and parental generations were recorded.

Close to 13,000 Swedish children ended up with an autism diagnosis, about 1.5 percent of the cohort. However, children whose mother had one or more siblings with autism were three times more likely to have ASD than the general population and children whose fathers had one or more siblings on the spectrum were twice as likely to be diagnosed with autism than the general population. The study considered the slightly higher autism risk rate of children from mothers who had a sibling with ASD to that of the fathers to be insignificant. The research also reported that the autism risk rate was not different if the parent had a brother versus a sister with autism.

Ultimately, the researchers found that 3 to 5 percent of children whose parents have a sibling on the spectrum also have autism themselves. This points to a 100 to 230% increased chance of developing the disorder compared to the 1.5 percent autism rate in the general population. According to the authors, this is the first epidemiological study to provide an autism risk estimate for children with aunts or uncles on the spectrum.

Continue reading "SafeMinds: Having an Aunt or Uncle with Autism May Put Children at Higher Risk of ASD" »


Beda Stadler Prof Emeritus Medical Faculty University of Bern: Coronavirus Why Everyone Was Wrong

Beda StadlerBeda M. Stadler, former Director of the University Institute of Immunology at the Insel Hospital in Bern, is emerited professor of Immunology from the Medical Faculty of the University of Bern. His major research interests were in basic research in the field of allergy and autoimmunity as well as applied research in the field of immunology.

As Vice President of the Commission for Technology and Innovation (CTI) Federal Department of Economic Affairs, Education and Research EAER Switzerland he was heading the life science team and was a member of the CTI Start-up & Entrepreneurship label board.

During his career he liked to express his scientific and rational views in public as a frequent guest speaker and columnist for various print media.

Posted on Medium.com: Coronavirus: Why everyone was wrong The immune response to the virus is stronger than everyone thought

The original article was published in the Swiss magazine Weltwoche (World Week) on June 10th. The author, Beda M Stadler is the former director of the Institute for Immunology at the University of Bern, a biologist and professor emeritus. Stadler is an important medical professional in Switzerland, he also likes to use provoking language, which should not deter you from the extremely important points he makes.

This article is about Switzerland and it does not suggest that the situation is exactly the same globally. I am advocating for local measures according to locale situations. And I advocate for looking at real data rather than abstract models. I also suggest to read to the end, because Stadler makes crucial points about testing for Sars-CoV-2.

The coronavirus is slowly retreating. What actually happened in the past few weeks? The experts have missed basic connections. The immune response against the virus is much stronger than we thought.

By Beda M Stadler

This is not an accusation, but a ruthless taking stock [of the current situation]. I could slap myself, because I looked at Sars-CoV2- way too long with panic. I am also somewhat annoyed with many of my immunology colleagues who so far have left the discussion about Covid-19 to virologist and epidemiologist. I feel it is time to criticise some of the main and completely wrong public statements about this virus.

Firstly, it was wrong to claim that this virus was novel. Secondly, It was even more wrong to claim that the population would not already have some immunity against this virus. Thirdly, it was the crowning of stupidity to claim that someone could have Covid-19 without any symptoms at all or even to pass the disease along without showing any symptoms whatsoever.

But let’s look at this one by one.

1. A new virus?

At the end of 2019 a coronavirus, which was considered novel, was detected in China. When the gene sequence, i.e. the blueprint of this virus, was identified and was given a similar name to the 2002 identified Sars, i.e. Sars-CoV-2, we should have already asked ourselves then how far [this virus] is related to other coronaviri, which can make human beings sick. But no, instead we discussed from which animal as part of a Chinese menu the virus might have sprung. In the meantime, however, many more people believe the Chinese were so stupid as to release this virus upon themselves in their own country. Now that we’re talking about developing a vaccine against the virus, we suddenly see studies which show that this so-called novel virus is very strongly related to Sars-1 as well as other beta-coronaviri which make us suffer every year in the form of a colds. Apart from the pure homologies in the sequence between the various coronaviri which can make people sick, [scientists] currently work on identifying a number of areas on the virus in the same way as human immune cells identify them. This is no longer about the genetic relationship, but about how our immune system sees this virus, i.e. which parts of other coronaviri could potentially be used in a vaccine.

So: Sars-Cov-2 isn’t all that new, but merely a seasonal cold virus that mutated and disappears in summer, as all cold viri do — which is what we’re observing globally right now. Flu viri mutate significantly more, by the way, and nobody would ever claim that a new flu virus strain was completely novel. Many veterinary doctors where therefore annoyed by this claim of novelty, as they have been vaccinating cats, dogs, pigs, and cows for years against coronaviri.

2. The fairy tale of no immunity READ MORE HERE


WHO's lead scientist Soumya Swaminathan places chief hope in Oxford and Moderna vaccines

image from www.fic.nih.govHaving systematically screwed up the hydoxychloroquine (HCQ) trials for the treatment of the Covid virus and otherwise prevented its general use, all of which likely ended up in countless unnecessary deaths (see Dr Meryl Nass's despairing assessment) the WHO are now turning their attention to the first crop of vaccines, created at reckless speed with new technologies. The WHO's chief scientist told Reuters on Friday:

GENEVA (Reuters) - AstraZeneca's <AZN.L> experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.

The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford.

This week, AstraZeneca signed its tenth supply-and-manufacturing deal.

"Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate," WHO chief scientist Soumya Swaminathan told a news conference.

The Oxford vaccine has a shaky history, funded to the tune of £90m million by the British government and taxpayer, and already in manufacture in billions of doses, the human trials began in April amid false reports that the animal trials had been successful: the product is arguably commercially too big to be allowed to fail. It also has the advantage that its lead developer Andrew Pollard heads the committee that will advise the British government on its use. Admittedly, last week he was in an apparently non-committal mood in conversation with Prince William:

Prof Pollard highlighted HIV, a virus for which no vaccine has been found because it mutates, saying scientists' great fear was that coronavirus could be the same. In that case, he said 'there is nothing we could do apart from social distancing forever' - a prospect William described as 'frightening'.

Continue reading "WHO's lead scientist Soumya Swaminathan places chief hope in Oxford and Moderna vaccines" »


Further Anomalies of the Oxford Coronavirus Vaccine

image from upload.wikimedia.orgby John Stone

On 27 April a New York Times article reported excitedly the result animal trials of the Oxford Coronavirus vaccine:

"Scientists at the National Institutes of Health’s Rocky Mountain Laboratory in Montana last month inoculated six rhesus macaque monkeys with single doses of the Oxford vaccine. The animals were then exposed to heavy quantities of the virus that is causing the pandemic... But more than 28 days later all six were healthy, said Vincent Munster, the researcher who conducted the test.."

This would have been just as well because just four days earlier on 23 April Oxford Vaccine Group under the leadership of Andrew Pollard amid immense publicity had begun experimenting on human subjects. On 30 April a contract was announced with AstraZeneca to manufacutre the vaccine, promising to deliver an entirely new vaccine to the market at unprecedented speed by September. The only trouble was that when the results of the animal trial came to light in mid-May it was disclosed that on the contrary all the monkeys had  become ill. The Daily Mail reported:

"In the latest animal trials of the vaccine carried out on rhesus macaques, all six of the participating monkeys went on to catch the coronavirus.

"Dr William Haseltine, a former Harvard Medical School professor, revealed the monkeys who received the vaccine had the same amount of virus in their noses as the three non-vaccinated monkeys in the trial.

This suggests the treatment, which has already received in the region of £90 million in government investment, may not halt the spread of the deadly disease."

Haseltine also commented in Forbes:

"There is a second troubling result of the Oxford paper. The titer of neutralizing antibody, as judged by inhibition of virus replication by successive serum dilutions as reported is extremely low. Typically, neutralizing antibodies in effective vaccines can be diluted by more than a thousand fold and retain activity. In these experiments the serum could be diluted only by 4 to 40 fold before neutralizing activity was lost."

Manifestly, human testing proceeded both against an entirely misleading background, and prematurely - which poses the most serious ethical questions. And now that we know that though the product was defective everything ploughs on regardless - Oxford/AstraZeneca now have contracts for hundreds of millions of rounds of the vaccine from both the British and the United States government.The British government has both a huge financial investment in the product and a reputational one, but it may help that Prof Pollard is both an adviser to the British regulator and chair of the committee recommends vaccine for public use.

John Stone is UK Editor for Age of Autism.

 

 

 


Professor Chris Exley: Aluminium in human brain tissue

AluminumExcerpted from the Blog of Professor Chris Exley, worldwide expert on aluminum and its effects on the human brain.

###

We have now measured the concentration of aluminium in human brain tissue from over two hundred donors involving at least five different brain banks. This equates to several thousand individual brain tissue samples. We have information relating to sporadic and familial Alzheimer’s disease, multiple sclerosis, cancer, epilepsy and autism. If I am honest, I am slightly bemused when, correctly, the question is asked about brain aluminium content in ‘control’ tissues. Bemused because such a question does suggest that the presence of an established neurotoxin, known to cause dialysis encephalopathy, is perhaps ‘normal’ and not a cause for concern.

We recently asked the question as to how much aluminium in human brain tissue is too much ( https://link.springer.com/article/10.1007%2Fs00775-019-01710-0) and we described an experiment in the paper to answer this question. We now have the data from this new study on the aluminium content of brain tissue from donors with no known neurological impairment and no identifiable neurodegenerative disease. The results are published in Nature’s Scientific Reports (www.nature.com/articles/s41598-020-64734-6) and they are unequivocal.

Read more from Professor Exley at Aluminium in human brain tissue at The Hippocratic Post


April 4 Expert Panel on COVID-19 & The Vaccines To Follow

Panel
Thank you to our Anne Dachel for transcribing excerpts for our readers.  Anne says:

"This was one of the most informative and empowering talks I’ve ever listened to in all the years I’ve been working as an autism advocate. Every person concerned about what the COVID 19 pandemic will do to our medical freedom needs to hear these speakers and learn the truth about what’s coming. There is no walking away from this threat to our liberties."

April 4, 2020, Panel discussion the COVID 19 crisis and what a vaccine could mean to the American people.

https://www.youtube.com/watch?v=cV_QPwWxOX8&feature=emb_share&fbclid=IwAR04nwi-CfzHYrIIgE5U00Gt7Z9ZBeht8N-3xzUtsHziHNHr8BuAKO0X6VQ


Panelists:

Dr. Andrew Wakefield, Dr. Judy Mikovits, Del Bigtree, Ty and Charlene Bollinger, Robert Kennedy, Jr., Dr. Sherri Tenpenny, Dr. Rashid Buttar.

Here are excerpts from the discussion.

Charlene: “…the year 2020 was a big deal. … This is the year, if we don’t help people understand this critical issue we may loss our freedoms, and they may be able to come in and try …to force us into these vaccines. But we did not know what we were getting into….

“I was watching Tucker Carlson  [Fox, Tucker Carlson Tonight]. He’s actually had Bobby Kennedy on…  We couldn’t believe that mainstream media outlet was covering that. We felt like Tucker’s our friend…

“Last night…on Tucker Carlson Tonight … He had a guest and they talked about Operation Wrap Speed, the COVID vaccination where they’re literally going to pass through the trials that they should be doing. They’re going to skip all that safety measures to get to this vaccine. They’re going to have a hundred million ready to go. …

“The guest talked about this as if it’s a good thing, and Tucker Carlson who has interviewed our good friend Bobby Kennedy, ….  I was really letdown by the fact that Tucker Carlson allowed that guest to say that and didn’t dig in. …”

5:42 Kennedy: “There’s now eighty separate vaccine projects. Bill Gates has eight of them. Bill Gates is now the biggest vaccine producer in the world, bigger than any other company.

Continue reading "April 4 Expert Panel on COVID-19 & The Vaccines To Follow" »


A Letter to My Member of Parliament: THE CRITICAL NEED FOR TRANSPARENCY AROUND COVID-19 VACCINES

image from pbs.twimg.comby John Stone

This is  the letter I sent to my Member of of Parliament yesterday forwarding the excellent  letter to the UK's Secretary of Health and Social Care, Matt Hancock (pictured with Bill Gates),  by Robert Verkerk and Damien Downing:

Dear ------,

 
RE: THE CRITICAL NEED FOR TRANSPARENCY AROUND COVID-19 VACCINES    
 
I am forwarding the excellent letter (attached) to Matt Hancock by Robert Verkerk of the Alliance for Nautal Health International and Damien Downing of the British Society for Ecological Medicine requesting transparency over the introduction of any COVID-19 vaccines in response to the current crisis, and I would suggest that it is necessary for the Secretary of State to make clear undertakings rather than vague professions of good faith. The letter can be found here on-line [1]. 
 
It was well understood even in the 19th century how statistics could be distorted for political purposes, since when the methods have only become more sophisticated and ultimately potentially more obfuscating. The safety, usefulness and effectiveness of universal vaccines should have to be meticulously and transparently established, yet we advance at reckless pace. It is certain that none of the candidates will have long term testing and it is questionable who on the face of it they could sensibly be given to [2].
 
There are other matters of transparency which go beyond the Verkerk/Downing letter. For example, the unusual arrangement by which the Secretary of State is also the main shareholder in the Porton Down Lab (as is now well-known). It was distressing to see how the Secretary of State began pumping public money into the speculative Porton Down vaccine project in the early stages of the epidemic, while failing to ensure that the puplic were immediately protected [3] (we are now heading for the worst fatality rate of any country). On the 19 March Public Health England put out a statement that they no longer considered COVID-19 to be a high risk disease [4] and within a day we were facing lockdown. Not much more convincing, now, are tub thumping references to British innovation by the Business Secretary or the Prime Minister.

Continue reading "A Letter to My Member of Parliament: THE CRITICAL NEED FOR TRANSPARENCY AROUND COVID-19 VACCINES" »


A New Route for Harm: Autism in the New Paper by Exley and Mold

AluminumWe recently published the abstract of a new paper by Exley and Mold 'Imaging of aluminium and amyloid β in neurodegenerative disease' which in particular offers new evidence ralating to the possible etiology of  autism. Prof Exley has elaborated:

"...the novel finding was the deposition of amyloid-beta and especially its presence in the vasculature similar to what is called cerebral amyloid angiopathy (CAA) in Alzheimer's disease. CAA could be interpreted as evidence of a toxin in the blood 'attempting' to cross the blood brain barrier to gain entry to brain tissue. CAA along with amyloid beta deposits in parenchyma does very much suggest brain damage and its presence in young brain donors is very surprising. It does raise the question if there are similarities between what is happening in brain tissue in autism and neurodegenerative diseases such as Alzheimer's disease."

It is stated in the paper:

"Our observations of amyloid β-like deposits in autism brain tissue are novel and may suggest neuropathology similar to that seen in CAA. We identified several examples of CAA in autism brain tissue as well as deposits of amyloid β in β sheet conformations in parenchymal tissues...Previous research identified diffuse deposits of amyloid β in brain tissue in older individuals with autism (39 and 50 years of age)...while herein amyloid β in β sheet conformations was confirmed in individuals with autism aged, 14, 15, 22, 33, 44 and 50 years of age.

Recently the non-amyloidogenic pathway of metabolism of amyloid precursor protein has been implicated in autism...while our observations suggest that the amyloidogenic pathway may also be important..."

It is obviously vital that this discovery is further investigated. Read the full paper here.

 


Imaging of aluminium and amyloid β in neurodegenerative disease

AluminumHeliyon, Science Direct

ChristopherExley, Matthew J.Mold

The Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire, United Kingdom

Received 10 December 2019, Revised 16 March 2020, Accepted 21 April 2020, Available online 25 April 2020.

https://doi.org/10.1016/j.heliyon.2020.e03839

Imaging of aluminium and amyloid β in neurodegenerative disease

Abstract

Objectives

Recent research has confirmed the presence of aluminium in human brain tissue. Quantitative analyses suggest increased brain aluminium content in a number of neurodegenerative diseases including familial Alzheimer's disease, congophilic amyloid angiopathy, epilepsy and autism. Complementary aluminium-specific fluorescence microscopy identifies the location of aluminium in human brain tissue and demonstrates significant differences in distribution between diseases. Herein we combine these approaches in investigating associations between aluminium in human brain tissue and specific disease-associated neuropathologies.

Methods

We have used aluminium-specific fluorescence microscopy, Congo red staining using light and polarised light and thioflavin S fluorescence microscopy on serial sections of brain tissues to identify co-localisation of aluminium and amyloid β and tau neuropathology.
Results

A combination of light, polarised and fluorescence microscopy demonstrates an intimate relationship between aluminium and amyloid β in familial Alzheimer's disease but not in other conditions and diseases, such as congophilic amyloid angiopathy and autism. We demonstrate preliminary evidence of amyloid β pathology, including associations with vasculature and parenchymal tissues, in autism in tissues heavily loaded with aluminium.

Conclusion

We suggest that complementary aluminium-specific fluorescence microscopy may reveal important information about the putative toxicity of aluminium in neurodegenerative and neurodevelopmental disorders.


FREE From Dartmouth Medical School Trained Dr. Paul Thomas COVID-19: The Life Saving Strategies the News Media Will Never Tell You

Dr Paul Covid Book
Thank you to Dr. Paul Thomas, MD for offering free downloads of his book COVID-19: The Life Saving Strategies the News Media Will Never Tell You.

Dr. Paul Thomas (affectionately known as “Dr. Paul”) received his MD from Dartmouth Medical School and completed is pediatric residency at the University of California, San Diego.

​Dr. Paul is a board-certified fellow of the American Academy of Pediatrics. FAAP. He is also trained in Integrative and Holistic Medicine. He is also a diplomate of the American Board of Addiction Medicine. ABAM.

Click HERE to register for your free copy today.

Dr. Thomas has over 1.2 million YouTube subscribers. Amazon banned the sale of this book on their site.  


MIT Technology Review: How does the coronavirus work?

MIT reviewExcerpted from the MIT Technology Review May 2020 issue:

How does the coronavirus work? What it is, where it comes from, how it hurts us, and how we fight it.

By Neer Patel

What is it?

A SARS-CoV-2 virion (a single virus particle) is about 80 nanometers in diameter. The pathogen is a member of the coronavirus family, which includes the viruses responsible for SARS and MERS infections. Each virion is a sphere of protein protecting a ball of RNA, the virus’s genetic code. It’s covered by spiky protrusions, which are in turn enveloped in a layer of fat (the reason soap does a good job of destroying the virus).
Where does it come from?

Covid-19, like SARS, MERS, AIDS, and Ebola, is a zoonotic disease—it jumped from another species to human hosts. This probably happened in late 2019 in Wuhan, China. Scientists believe bats are the likeliest reservoir; SARS-CoV-2’s closest relative is a bat virus that shares 96% of its genome. It might have jumped from bats to pangolins, an endangered species sometimes eaten as a delicacy, and then to humans.

How does it get into human cells?

Continue reading "MIT Technology Review: How does the coronavirus work?" »


British Government Plays With Fire Over COVID-19: Enter Prof Pollard

image from en.wikipedia.orgby John Stone

Next week Over Vaccine Group begin human testing for a COVID-19 vaccine with a with a view to marketing by the autumn. The speed of the process may be accelerated by the fact that Professor Pollard who heads the OVG is also advisor to the the UK's licensing body, the MHRA, and chair of the JCVI, the body which recommends vaccines to the British schedule. He very likely also sits on the British government’s mysterious Scientific Advisory Group for Emergencies.  Age of Autism has been higlighting the manifold and apparently contradictory roles of Prof Pollard for more than four years. In 2014 as recently appointed chair of the JCVI he recommended Bexsero meningitis B vaccine of which he was lead developer to the UK infant schedule, leading to a sudden leap in its commercial prospects. Even the package insert discloses serious dangers for Bexsero including a 3 in 1000 risk of Kawasaki Disease for an infant having three doses. 

While Pollard and likely the British government's plans rush forward many scientists have questioned either the wisdom of the COVID-19 vaccine or how fast one could be brought to the market. On the present time scale we will know nothing of the long term effects. Tests will be carried on healthy people 18-55 but rolled out for children, the sick and the elderly. It will be trialled against "a control injection" not genuine placebo, (in fact a Men ACWY vaccine). At present we do not even know if the disease itself results in long term immunity or any immunity against all the other mutations which are beginning to proliferate. Meanwhile, the OVG promotes discussion about whether vaccination should be made compulsory. Indeed, if it were it would be Prof Pollard's committee which would decide what every man, woman and child in the United Kingdom would receive, and would not be able to refuse.

This is Pollard’s most recent disclosure in the JCVI minutes:

Professor Pollard receives no personal payments from the manufacturers of vaccinesHe is Director of the Oxford Vaccine Group in the Department of Paediatrics, University of Oxford and has current research funding from the Bill and Melinda Gates Foundation, the National Institute for Health Research, the European Commission, Medical Research Council, Wellcome Trust, InnovateUK, Meningitis Research Foundation, and the Global Alliance for Vaccines and Immunisation. Hechairs the scientific advisory group on vaccines for the European Medicines Agency and is a memberof WHO’s SAGE.Other investigators in the Department conduct research funded by vaccine manufacturers and theDepartment has received unrestricted educational grant funding for a three-day course on paediatricinfectious disease from Gilead, and GSK in June 2019.

While it is inevitable that any scientist is going to be an enthusiast for is or her own research the long term indifference of the British government to traditional checks and balances is deeply concerning, and no less so at this difficult time. 


Recruitment begins for a clinical trial of a COVID-19 vaccine led by Andy Pollard

andrew pollard

Professor Andrew Pollard, Vice Master of St Cross College, is the Chief Investigator on a new study developing a possible vaccine for COVID-19. The 'ChAdOx1 nCoV-19' vaccine, as it is called, was developed by a team of University of Oxford researchers based on an adenovirus vaccine vector. A collaborative team from the Jenner Group and the Oxford Vaccine Group is now recruiting over 500 healthy volunteers for clinical trials of the vaccine. While applications for volunteers have closed, those interested in volunteering for future COVID-19 studies can register interest here.

Pollard is one of a team of academics, which includes himself, Professor Sarah Gilbert, Professor Teresa Lambe, Dr Sandy Douglas and Professor Adrian Hill, who began the project on Friday 10 January 2020. Pollard said, ‘Starting the clinical trials is the first step in the efforts to find out whether the new vaccine being developed at Oxford University works and could safely play a central role in controlling the pandemic coronavirus that is sweeping the globe.’

You can read more about the study here.

Riley Lewis

7 April 2020


Aluminium in Brain Tissue in Non‑neurodegenerative/ Non‑neurodevelopmental Disease: A Comparison with Multiple Sclerosis

Annette_Funicello_Former_Mouseketeer_1975Note:  In 1993, my husband won a sales award with his company and we were able to take a trip for four days. I chose DisneyWorld in Orlando. We stayed at the elegant Victorian hotel. One afternoon, I went into a ladies room in the lobby and behind me, in walked in Annette Funicello, with a lucite cane that was filled with glitter. I'll never forget it. We were in the ladies room, which meant we had business to conduct, and I didn't want to embarrass Ms. Funicello.  But I had to say SOMETHING. This was America's Sweetheart! I'd watched her beach movies. I knew she was the most famous Mouskateer.  I'm proud of what came out of my mouth! I said, "Oh, Ms. Funicello, now I really feel like I am in DisneyWorld because I saw  you."  She smiled at me. Funicello died at age 70 from MS. This beautiful girl, gorgeous woman, was destroyed by the disease.

I tell you this because when we read science, like this study from Chris Exley and his colleagues, the conclusions affect real lives. I tell you this, why?

"Because we like you."  M-O-U-S-E.

Vol.:(0123456789)1 3
Exposure and Health https://doi.org/10.1007/s12403-020-00346-9
ORIGINAL PAPER
|
Aluminium in Brain Tissue in Non‑neurodegenerative/Non‑neurodevelopmental Disease: A Comparison with Multiple Sclerosis

C. Linhart1 · D. Davidson2 · S. Pathmanathan2 · T. Kamaladas2 · C. Exley3Received: 5 October 2019 / Revised: 7 February 2020 / Accepted: 15 February 2020 © The Author(s) 2020

Abstract

Human exposure to aluminium is a burgeoning issue. The brain is a sink for systemically available aluminium and a putative target of neurotoxicity. An increasing number of studies continue to confirm the presence of aluminium in human brain tissue though primarily in relation to donors who have died of a neurodegenerative or neurodevelopmental disorder. Herein, we have measured aluminium in brain tissue in donors who died of a specific disease or condition though without showing any neurodegeneration. The donors were diagnosed as not suffering from multiple sclerosis. Herein, these novel data are compared with recent data on aluminium in brain tissue in multiple sclerosis. Brain tissues from all four lobes were obtained from the Multiple Sclerosis Society Tissue Bank. Tissues were digested using microwave-assisted acid digestion and their aluminium content was measured by transversely heated graphite furnace atomic absorption spectrometry. Both are established methods in our laboratory. Detailed statistical analyses were used to compare new data with recent data for multiple sclerosis. Aluminium was found in brain tissue in each donor with a high proportion of measurements (189/291) being below 1.00 μg/g dry weight. The data for all cases (median and IQR) were 0.74 (0.48–1.28), 1.23 (0.62–1.63), 0.84 (0.45–1.14) and 1.01 (0.62–1.65) μg/g dry weight for occipital, parietal, temporal and frontal lobes, respectively. There was a statistically significant positive correlation between aluminium content of brain tissue and the age of donor. Comparison of data for this non-multiple sclerosis group with brain aluminium data for donors dying with a diagnosis of multiple sclerosis showed that the latter had a statistically significant higher content of brain aluminium. The data reinforce a previous conclusion that the aluminium content of brain tissue in multiple sclerosis is elevated and support the suggestion that human exposure to aluminium may have a role to play in the aetiology of multiple sclerosis. Keywords Human exposure to aluminium · Aluminium in brain tissue · Aluminium in multiple sclerosis · Aluminium and neurodegenerative disease · Aluminium and neurodevelopmental disease  Read the paper here.


The Latest Autism Gene Study: NIH Director Collins Hails Deliberate Waste of Time, Money and Lives...

image from encrypted-tbn0.gstatic.comBy John Stone

In a short article in Southern Maryland Chronicle a few days ago the Head of the National Institutes of Health, Francis Collins, hailed the latest autism gene study under the title 'Largest-Ever Genetic Study of Autism Yields New Insights'. Perhaps the message here is that in order to fight crime the government has decided to investigate the victims not the perpetrators (actually it has been doing this for three decades). In 2006 as Head of the Human Genome Project Collins told Congress:

"But genes alone do not tell the whole story. Recent increases in chronic diseases like diabetes, childhood asthma, obesity or autism cannot be due to major shifts in the human gene pool as those changes take much more time to occur. They must be due to changes in the environment, including diet and physical activity, which may produce disease in genetically predisposed persons. Therefore, GEI (the Genes and Environment Initiative) will also invest in innovative new technologies/sensors to measure environmental toxins, dietary intake and physical activity, and using new tools of genomics, proteomics, and understanding metabolism rates to determine an individual's biological response to those influences."

References on-line to GEI seem to peter out round about 2008 (perhaps they were in danger of finding something). So, 14 years ago Collins warned that there would be no material result from this kind of research and it is what the government have been doing ever since, more or less as an employment scheme (typically, the new study boasts nearly two hundred authors). As Eisenhower said to no avail in his farewell speech six decades ago:

"Today, the solitary inventor, tinkering in his shop, has been overshadowed by task forces of scientists in laboratories and testing fields. In the same fashion, the free university, historically the fountainhead of free ideas and scientific discovery, has experienced a revolution in the conduct of research. Partly because of the huge costs involved, a government contract becomes virtually a substitute for intellectual curiosity....

"The prospect of domination of the nation's scholars by Federal employment, project allocations, and the power of money is ever present and is gravely to be regarded.

"Yet, in holding scientific research and discovery in respect, as we should, we must also be alert to the equal and opposite danger that public policy could itself become the captive of a scientific/ technological elite."

Now - with whatever insights their may be into gene risk association or even patterns of damage - is that all the NIH have really succeeded in doing is  generating  a lot more data: the new study is not only "the largest ever" it is "the largest-ever" in NIH speak (and with a huge cast), but in terms of government approved science we are not an inch nearer discovering what is driving the autism epidemic, just as Collins told Congress it would not all those years ago: it is all one giant step for mankind to nowhere. Meanwhile, the autism rate in schools is perhaps 4 or 5 times higher than it was then: it is rather hard to tell because NIH and CDC have failed to monitor it in any systematic way.

When I started out on this trail I recall a meeting at a freezing local church hall in early 1997 addressed by Paul Shattock, now of the ESPA Autism Research Unit, Sunderland. One of the many and terrible things Paul told us was that 90% off the funding into the causes of autism was being swallowed by useless gene research, meanwhile the problem was ten times as bad as ten years before. He foretold exactly was going to play out. How appalling and cynical this charade has been.

If you want to turn a disaster into a catastrophe and catastrophe into a cataclysm send for Collins!!!

John Stone is UK and European Editor, Age of Autism

 

 

 

 

 

 

Editor of Age of Autism

 

 


Coronavirus Can Be Caused By Viral Interference, A Known Result Of Flu Vaccines

Science post imageNews and articles about CORONAVIRUS are everywhere but our article, here on Age Of Autism, may be much different from what we are reading and seeing elsewhere.  It is interesting to observe the business side of all of this talk of health.  This from Business Insider, for example:

The flu is a far bigger threat to most people in the US than the Wuhan coronavirus. Here's why.

Although the CDC considers this coronavirus (whose scientific name is 2019-nCoV) to be a serious public-health concern, the agency said in a statement Friday that "the immediate health risk from 2019-nCoV to the general American public is considered low at this time."

A graver health risk for Americans — not just right now, but every year — is the flu….."When we think about the relative danger of this new coronavirus and influenza, there's just no comparison," William Schaffner, a vaccine expert at Vanderbilt University Medical Center, told Kaiser Health News (KHN). "Coronavirus will be a blip on the horizon in comparison. The risk is trivial."....So far, experts report that the median age of those who have died from the Wuhan coronavirus is around 75. Many of these individuals had other health issues like high blood pressure, diabetes, and Parkinson's disease…..Currently, the fatality rate for the coronavirus is about 3%. 

While the flu's fatality rate is lower than that, the CDC is still far more concerned about protecting Americans from influenza.

And there you have it.  Like Ralphie in A Christmas Story, it’s all about selling Ovaltine, but in this case, it’s the flu vaccine, which can be ineffective, we are told https://www.scientificamerican.com/article/flu-vaccine-selections-suggest-this-years-shot-may-be-off-the-mark/ .  As a result, you can bet lots of money is being lost and it sure looks like this virus in China has become a good excuse to get rid of these flu vaccines.  Another business piece that is obviously revving up, is to invent a coronavirus vaccine.

Honestly, just reading up on both influenza and coronavirus brings up some interesting reading.  For starters, it appears in China, that this year, there were twice as many flu shots being given:

Continue reading "Coronavirus Can Be Caused By Viral Interference, A Known Result Of Flu Vaccines" »


Negative Efficacy: UK Cervical Cancer Rate Rising in Teens Vaccinated for HPV

CevarixzImagine the horror of learning your young daughter has cervical cancer, once a rare disease, after having trusted that the HPV vaccine would prevent this disease.

From Children's Health Defense:

Bombshell Study Questioning HPV Vaccine Efficacy Appears as the UK’s Cervical Cancer Rates Rise in Young

Human papillomavirus (HPV) vaccines hit the global marketplace in the mid-2000s. From the start, public health agencies enthusiastically promoted HPV vaccination as the “best way to protect [young people] against certain types of cancer later in life.” However, a blistering new study by British researchers—and new data showing that cervical cancer rates are surging in British 25- to 29-year-olds—raise numerous questions about officials’ inflated claims. The study’s results indicate, instead, that the jury is still out on whether HPV vaccination is effective.

The question is far from academic because, prior to Britain’s introduction of HPV vaccination in 2008, cervical cancer rates had been trending sharply downward. In fact, between the late 1980s and mid-2000s, cervical cancer rates halved. Now, Britain’s leading cancer research charity (Cancer Research UK) reports a steep 54% rise in cervical cancer in one of the very age groups that first received the vaccine.

The 2020 study, published in the Journal of the Royal Society of Medicine, critically appraises twelve published randomized controlled trials that HPV vaccine makers GlaxoSmithKline and Merck used to buttress assertions about their vaccines’ efficacy (Cervarix and Gardasil). The British authors do not beat around the bush in presenting their conclusions, which include the following:

  • The trials’ questionable methodology generated “uncertainties” so significant that they undermine claims of efficacy.
  • The ages of the women who participated in the trials were not representative of the younger adolescents who constitute HPV vaccination’s primary target groups.
  • The studies used highly restrictive criteria to exclude many potential participants, limiting the trials’ “relevance and validity for real world settings.” (During Science Day presentations for the Jennifer Robi vs. Merck and Kaiser Permanente Gardasil lawsuit in January 2019, Robert F. Kennedy, Jr. made the same point, describing the “elite club of superheroes” who constituted the study group and noting that Merck purged anyone with the slightest vulnerabilities to the vaccine or its ingredients despite the fact that the vaccine would ultimately be marketed to girls with the very vulnerabilities excluded during the clinical trials.)
  • The trials used “composite and distant surrogate outcomes” that essentially made it “impossible to determine effects on clinically significant outcomes.” The authors explain that the surrogate outcomes used (forms of cervical dysplasia called CIN1 and CIN2) often regress on their own “and are of limited clinical concern.” They also note that different forms of cervical dysplasia each have “their own different natural histories, prevalence and incidence and strength of association with cancer.” Lumping together vastly different forms of dysplasia into the trials’ composite surrogate endpoints, therefore, was “problematic.”

    Read the full reports at Children's Health Defense here.

Journal Of Alzheimer's Disease: Aluminum and Amyloid-β in Familial Alzheimer’s Disease

Alzheimers generations
Note: One wonders why this isn't front page news, instead of a new virus in China (for which is a vaccine is in the works) and rare Ebola (for which a vaccine is coming out.) Alzheimer's affects at least three generations at a pop.  When a grandparent succumbs, Mom and Dad (the sandwich generation) may race through savings and certainly face exhaustion finding care.  Their children pay a price. The parallels in care and behavior to an autism diagnosis are heart breaking. Yet aluminum is prevalent in day to day living and in bolus presence in many vaccines. Deodorants and antacids tout being aluminum free as a selling point.  Still, the topic is verboten when an adjuvant in vaccines.  Vaping and e-Cigs were ripped in headlines quickly for safety concerns. Just last week, I got 3 fliers in the mail from my daughters CT Medicaid talking about the dangers of vaping.  Imagine the expense, and vaping isn't mandated or pushed by doctors, stores, the media. It's a legal product one chooses.   Doctors tell women to have genetic tests for breast cancer, and many women choose preventive mastectomy to prevent the disease. With aluminum and Alzheimers, the aluminum is foisted upon us and we're ridiculed if we say, NO.

Here is a study  that includes Professor Chris Exley that should chill every reader, if the media would only publish it.

###

Article type: Research Article

Authors: Mold, Matthewa | Linhart, Carolineb | Gómez-Ramírez, Johanac | Villegas-Lanau, Andrésc | Exley, Christophera; *

Affiliations: [a] The Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire, United Kingdom | [b] Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Innsbruck, Austria | [c] Grupo de Neurociencias de Antioquia, Sede de Investigación Universitaria SIU, Medellín, Colombia

Correspondence: [*] Correspondence to: Professor Christopher Exley, The Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire, ST5 5BG, United Kingdom. E-mail: c.exley@keele.ac.uk.

Keywords: Aluminum in human brain tissue, amyloid-β, familial Alzheimer’s disease, human exposure to aluminum

DOI: 10.3233/JAD-191140

Journal: Journal of Alzheimer's Disease, vol. Pre-press, no. Pre-press, pp. 1-9, 2019
Accepted 16 December 2019
| Published: 13 January 2020

Abstract

Genetic predispositions associated with metabolism of the amyloid-β protein precursor underlie familial Alzheimer’s disease; a form of dementia characterized by early disease onset and elevated levels of cortical amyloid-β. Human exposure to aluminum is linked to the etiology of Alzheimer’s disease and recent research measured a high content of aluminum in brain tissue in familial Alzheimer’s disease. To elaborate upon this finding, we have obtained brain tissues from a Colombian cohort of donors with familial Alzheimer’s disease. We have used established methods to measure the aluminum content of these tissues and we have compared the data with a recently measured dataset for control brain tissues. We report significantly higher levels of aluminum in brain tissues in donors with familial Alzheimer’s disease than in control tissues from donors without neurological impairment or neurodegeneration. We have used aluminum-specific fluorescence microscopy along with complementary imaging for amyloid-β to demonstrate a very high degree of co-localization of these two risk factors in brain tissue in familial Alzheimer’s disease. Aluminum and amyloid-β were co-located in senile plaques as well as vasculature, the latter resembling cerebral amyloid angiopathy. Aluminum was also found separately from amyloid-β in intracellular compartments including glia and neuronal axons. The research has identified an arguably unique association between high brain aluminum content and amyloid-β and allows postulation that genetic predispositions defining familial Alzheimer’s disease underlie this relationship.

Continue reading "Journal Of Alzheimer's Disease: Aluminum and Amyloid-β in Familial Alzheimer’s Disease " »


Infants are Uniquely Vulnerable to Aluminium in Vaccines

AluminumInfants are Uniquely Vulnerable to Aluminium in Vaccines

Professor Chris Exley | 9th January 2020 | Infection/Disease, Paediatrics, Pharmacy/Drugs
The Hippocratic Post

Aluminium is Toxic

In 1984, as an undergraduate at the University of Stirling, Scotland and while carrying out my first piece of independent research, I watched for the first time a fish, a salmon parr, die from acute aluminium toxicity. The whole process took less than forty-eight hours. Within six hours, the fish showed signs of distress and its behaviour changed markedly. It proceeded to seek out the corners of the tank, pushing its head and body against the side of the tank. After twenty-four hours, it began to move randomly and chaotically around the tank before losing its orientation, slipping onto its back, taking a last gasp, before dying. I was left in no doubt about the toxicity of aluminium. I am recalling this event herein because there does seem to be significant complacency concerning the toxicity of aluminium.

An Aluminium Adjuvant is Acutely Toxic Too

In a recent post (https://www.hippocraticpost.com/pharmacy-drugs/the-toxicity-of-aluminium-adjuvants/) I explained why a single injection of a vaccine that includes an aluminium adjuvant is, akin to the salmon above, also an acute exposure to aluminium. It is acute because the total concentration of aluminium in the immediate vicinity of the injection site is extremely high, in the case of a single dose of Infanrix Hexa vaccine, approximately 8000 times higher than is required to kill a salmon parr within forty-eight hours. Even allowing for some dilution of the injected aluminium adjuvant into body fluids bathing and innervating the tissues surrounding the injection site the total concentration of aluminium in a vaccine is sufficient to cause cell death within hours and perhaps minutes of receiving the injection. This is the definition of an acute response, death (cells or whole organism) within a short period of exposure to a toxin. It is a necrotic form of cell death. It initiates an inflammatory response (redness at the injection site). This inflammation drives and perhaps accelerates the subsequent immune response (https://www.hippocraticpost.com/infection-disease/safety-concerns-aluminium-adjuvants/). A number of mechanisms bring about remediation of acute aluminium toxicity at a vaccine injection site. These are chemical, physical and biological. The toxic free metal ion, Al3+, forms soluble and insoluble complexes with myriad biological molecules while particles of aluminium adjuvant and other insoluble aluminium compounds are taken up by cells infiltrating the vaccine injection site. All of these processes act to reduce the acute toxicity of aluminium at the injection site by lowering the immediate concentration of toxic Al3+. These remedial processes act to secure aluminium in a number of different compartments. All are systemic and all are potential sources of biologically reactive aluminium to the rest of the body. Many chemical compartments where aluminium is bound in myriad different complexes including simple organic moieties like citrate or more complex proteins like the iron transport protein transferrin promote the transport of aluminium away from the injection site. These processes can be envisaged as continuous passive diffusion of soluble aluminium away from the injection site. The majority of injected aluminium adjuvant is particulate in the first instance and actively taken up, literally eaten, by a number of different cells infiltrating the injection site. Some particles of aluminium adjuvant are taken up by macrophages and thereafter they are retained at or close to the injection site as a granuloma. Generally, these collections of macrophages are considered as benign ‘cancers’ though such descriptions have been coined for situations where the cellular cargo is not aluminium. For example, macrophagic myofasciitis or MMF is a disease, first described by Romain Gherardi in Paris, in which aluminium-rich granulomas at vaccine injection sites are implicated in disease aetiology. Other cells heavily laden with aluminium do not remain close to the injection site and carry their cargo well beyond where the vaccine is administered, for example visiting local lymph nodes as early stops on their travels. Evidence is mounting that these cells may transport aluminium into brain tissue using both lymph and blood as access routes. Perhaps most worrying, evidence of transport of aluminium into brain tissue across the blood-brain barrier and meninges has been shown in autism (https://www.hippocraticpost.com/infection-disease/aluminium-and-autism/). Read more and comment at The Hippocratic Post.


Yet Another "RARE" Autoimmune Disease Caused By Vaccines

Vaccines colorfulBy Teresa Conrick

This case study, just recently out, shows a bad result and we cannot deny its existence: 

✹    Man Develops Autoimmune Hemolytic Anemia After Getting Flu Vaccine, Case Study Reports  DECEMBER 3, 2019

The case highlights the importance of educating patients to report any unusual symptoms after vaccination.

The study, “Autoimmune Hemolytic Anemia in a Renal Transplant Patient Following Seasonal Influenza Vaccination,” was published in the journal Case Reports in Hematology.

Autoimmune hemolytic anemia, or AIHA, occurs when the immune system mistakenly attacks the body’s own red blood cells, causing a reduction in the number of these cells and leading to hemolytic anemia.

Symptoms may include weakness, fatigue, and jaundice. Cold agglutinin disease (CAD) is one of the most common forms of AIHA, marked by the formation of autoantibodies against red blood cells formed upon exposure to cold temperatures.

AIHA can have an unknown origin or result from an underlying disease or medication. Vaccines have been associated with triggering this condition.

This report described the case of a man, age 58, who received a seasonal flu vaccine (quadrivalent inactivated influenza vaccine IIV4) as part of routine care.

That may have been considered a “rare” occurrence but researching Autoimmune Hemolytic Anemia brought the following case studies up, also as a result of vaccination.  It’s important people are aware of this as it is a serious consequence, not always medically investigated, and can be fatal. 

Case in point: 

OFFICE OF SPECIAL MASTERS

DECISION

MILLMAN, Special Master On January 28, 1999, petitioner filed a petition on behalf of her daughter, Lauren Brown (hereinafter, “Lauren”),for compensation under the National Childhood Vaccine Injury Act of 19861 (hereinafter the "Vaccine Act" or the "Act"). ...Petitioner alleges that Lauren’s vaccinations were a substantial factor in Lauren’s contraction of hemolytic anemia, causing her death. Respondent denies causation. The court held a hearing in this case on May 10, 2000. Testifying for petitioner was Dr. Ralph Shapiro. Testifying for respondent was Dr. Gregory H. Reaman. Both are specialists in pediatrics, oncology, and hematology….

Continue reading "Yet Another "RARE" Autoimmune Disease Caused By Vaccines" »


The Echo-Chambers of Public Health

Heads in the sandBy John Stone

Some readers may recall back in August following the pronouncements of British Prime Minister, Boris Johnson, about clamping down on vaccine misinformation. I tried to help by reviewing our National Health Service webpage 'Vaccines are safe and important'. It may be said the web-managers were perfectly courteous but referred my comments to "Public Health England Immunology Team" who took no less than 106 days to reply. I was expecting something really good, considered expert replies to all my criticisms. What actually arrived was nothing but links to other web-pages committing similar solecisms and evasions. Reproducing the letter could apparently open me to draconian penalties but fundamentally the taunt about the "echo-chambers of social media" turns out to be nothing but projection: all they can do when challenged is repeat the propaganda. MISINFORMATION IS INFORMATION THE GOVERNMENT DOES NOT LIKE

Review of the United Kingdom National Health Service webpage ‘Why vaccination is safe and important’ (media reviewed 30 July 2019).

I am responding to claims or statements in this web-document ' Why vaccination is safe and important' [1] (not following the original order of presentation). 

I begin with the statement:

“(Vaccines) do not overload or weaken the immune system - it's safe to give children several vaccines at a time and this reduces the amount of injections they need”

It is not clear what the evidential basis is for this statement. Formerly, at least, British health officials were keen to cite a paper by Offit et al (2002) which suggested absurdly an infant could withstand 10,000 vaccines at a time. However far-fetched, this was based on a theoretical claim about routine exposure to environmental antigens. Evidently some environmental exposures are more dangerous than others, otherwise people would not be at risk from infectious diseases at all, but the basis of exposure through vaccination is different (injected), and involves adjuvants so it is perhaps not relevant at all to talk about the number of antigens (as in Offit). In August 2004 Dr Salisbury distinguished in an e-letter to me between the increased risk of adverse reactions in an extended schedule and “overload”, which begs the question what is meant by “overload” and what people are supposed to understand by such a statement. A paper by Aaby et al (2012) was entitled “Vaccine programmes must consider their effect on general resistance”, which is evidently a warning that there is no such blank cheque for expanding the schedule. I covered this ground in my published submission to the House of Commons Health and Social Care Committee inquiry into anti-microbial resistance last year [2]. The NHS need to clarify what they mean, but also state what the evidential basis is for this claim.

Another statement apparently contradicts the proposition that there is anything inherently safe about vaccinating:

“(Vaccines) get safety tested for years before being introduced - they're also monitored for any side effects”

Continue reading "The Echo-Chambers of Public Health" »


The Ubiquitous Prof Pollard: How Serious is British Medical Journal About Commercial Influence?

Pollardandrew2.previewby John Stone

Recently, British Medical Journal has been signalling an ambitious  intent to rid public health of commericial influence 'COMMERCIAL INFLUENCE IN HEALTH: FROM TRANSPARENCY TO INDEPENDENCE', but how serious is it? In this regard I wrote first to its on-line correspondence column, Rapid Responses, and then when my letter was not published to the lead author of the pilot paper Roy Moynihan and journal's editor in chief, Fiona Godlee, which in turn was not replied to. I was drawing their attention to the story familiar in the pages of Age of Autism of Prof Andrew Pollard.

Prof Pollard is the lead developer among other things with Oxford Vaccine Group (OVG)  of the Meningitis B vaccine, Bexsero. OVG, which is also part of Oxford University, develops vaccines in partnership with the pharmaceutical industry. Back in 2013 Oxford Vaccine Group became affiliated to the newly created agency Public Health England (PHE), a mysterious agglomerate body working within the United Kingdom National Health Service which seems to have been created with the intention of escaping normal governmental accountability.

Shortly after its creation the then Secretary of State for Health, Jeremy Hunt, wrote to the Joint Committee on Vaccination and Immunisation (JCVI), the committee which recommends vaccines to the NHS schedule (and is also affiliated to PHE),  to urgently consider the case for Bexsero. The JCVI passed over this unusual request in June 2013 but Prof Pollard was himself appointed to head the JCVI for the very next meeting in October 2013, and under his chairship the vaccine was recommended to the infant schedule at his second meeting in February 2014. Soon after this event negotiations began for GSK to take over the vaccine division of Novartis which manufactured Bexsero, and these were completed early in 2015. This was by chance just in time for Hunt to come to an agreement with GSK over the provision of Bexsero and for him to announce the deal before the May 2015 general election. The commercial prospects of the product took off.

This is just part of the picture. Prof Pollard is adviser to the British and European licensing agencies, he sits on the board of the Jenner Vaccine Foundation until earlier this year with Dr Norman Begg Vice-President and Chief Medical Officer of  GSK Biologicals: he has connections with many products which are recommended by the JCVI. If BMJ did not think the instance was relevant Moynihan could have written to explain their position. Instead there is silence, while they back off discussing facts which are well inside the public domain, if largely hidden.

BMJ need to show they mean business.

The correspondence to -  but not with BMJ - is below.

Dear Prof. Moynihan,

I do not know whether there could be legal reasons why...has not posted on-line my letter of 5 December (see below) but there could not be a network of influence more germane or central to the issues you and BMJ are raising. This is certainly not a personal issue about Prof Pollard, but the ubiquitousness of his name poses extremely serious questions. The director of Oxford Vaccine Group (an agency of Public Health England) which develops vaccines with the industry is also the Chair of the Joint Committee on Vaccination and Immunisation (another agency of PHE) which recommend products to the UK schedule. He also acts as an advisor  to the MHRA  and  EMA, which was extensively discussed in the Nordic Cochrane complaints  about HPV vaccines. OVG took part as well in trials of the controversial Pandemrix vaccine in 2009 prior to marketing. I am just sketching in a few issues which could extend over many products.

It is not my view that Prof Pollard is individually to blame for this opaque situation since all these institutions are presumably aware of the potential conflicts and allow them to continue. I personally raised the problem of the OVG/JCVI conflict with the DH, PHE and in the Scottish Parliament to no effect. But I do believe there is an obligation for those who know about these problems to bring them into the light of day, and this could not be an area of greater legitimate public concern. I hope BMJ will see fit to act.

I also attach for information the GSK document 'Evening of Evidence' 30 September 2015.

With all good wishes,

John Stone (UK Editor, Age of Autism)

34 Outram Road, London N22 7AF

44 20 8888 7109 

cc Fiona Godlee, ...

Re: Pathways to independence: towards producing and using trustworthy evidence - the case of vaccines

Dear Editor

I express concern about the prestige and doctrine of quasi-infallibility accorded to vaccines, which even put them in a different category from other medical products [1]. The assumption that all medicines are double blind placebo safety tested  was called into question in these columns in relation to vaccines earlier this year and unfortunately not satisfactorily answered [2]. It often seems that the imperative to ward against infectious disease has itself become reckless.

Continue reading "The Ubiquitous Prof Pollard: How Serious is British Medical Journal About Commercial Influence?" »


Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation

AluminumYet another damning article about the aluminum exposure of infants through vaccine products. 
 
For Immediate Release - Pittsburgh, PA

1. A study of the toxicity of the doses of aluminum in vaccines, led by Dr. James Lyons-Weiler of the publicly funded Institute for Pure and Applied Knowledge, was motivated by an absence of appropriate testing of aluminum safety testing in vaccines. Dosage safety testing of metals in vaccines is not required by federal regulatory bodies. 

2. The research represent an objective and independent evaluation of an important aspect of the CDC's vaccine schedule safety. 

3. The study builds on prior work that established a "safe" baseline of Al in vaccines for infants derived from FDA limits for adults, corrected for body weight per dose. 

4. A Key Finding is that the CDC schedule likely induces Al toxicity in newborns for over 70 percent of their days in the first seven months of life. This represents chronic aluminum toxicity during a critical period of brain development.

5. The IPAK research team, which included a Board-certified pediatrician, also studied an alternative schedule (the "Vaccine Friendly Plan") and found can be expected to result in aluminum toxicity in only 5% of days over the same time period.

6. In the study discussion, the team has called on the FDA to conduct dose-escalation studies of body-weight adjusted injected forms of aluminum in infant mice to assess the safety of the CDC recommended schedule for humans.
 
Aluminum is known to induce autoimmunity in mice, rats, and humans. About 60% of vaccines on the CDC schedule contain aluminum. 
 
Ongoing research by scientists at IPAK includes a study of the effects of CDC recommended catch-up schedules on aluminum chronic and total toxicity, and to define strategies to reduce total aluminum load during catch-up efforts via careful brand choice and spacing out aluminum-containing vaccines.  Tens to hundreds of thousands of families are expected to vaccinate their older children for the first time due to loss of religious and medical exemptions, and therefore pediatricians should especially take heed of the findings of this study. 
 
This research is expected to reduce the incidence of autoimmune disorders in US children and adults.
 
Press inquiries (Dr. JLW interview): Contact Gretchen Fagan (gfagan@ipaknowledge.org)

Journal of Trace Elements in Medicine and Biology

Volume 58, March 2020, 126444

Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation

Author links open overlay panel GrantMcFarlandaElaineLa JoieaPaulThomasbJamesLyons-Weilera

Abstract

Like the mechanisms of action as adjuvants, the pharmacodynamics of injected forms of aluminum commonly used in vaccines are not well-characterized, particularly with respect to how differences in schedules impact accumulation and how factors such as genetics and environmental influences on detoxification influence clearance. Previous modeling efforts are based on very little empirical data, with the model by Priest based on whole-body clearance rates estimated from a study involving a single human subject.

Continue reading "Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation" »


New From Prof. Chris Exley Aluminium Adjuvants in Vaccines: Missing Information

AluminumBelow is an excerpt from the latest from Professor Chris Exley, in The Hippocratic Post blog.

###

I have been researching human exposure to aluminium for over thirty-five years. I am (sometimes affectionately) known as Mr Aluminium. About ten years ago, I became interested in aluminium adjuvants and specifically how they help to potentiate the immune response in vaccination. Funded initially by the Medical Research Council (Nanotoxicity of Aluminium Adjuvants) we set about testing dogma associated with their mechanism of action in vaccines. We have recently reviewed this subject including our own research in the field (https://aacijournal.biomedcentral.com/articles/10.1186/s13223-018-0305-2). There are, of course, more questions remaining than answers obtained but we do now have a nascent understanding of the mode of action of aluminium adjuvants. It is clear that a vaccine including an aluminium adjuvant is an acute exposure to aluminium (https://www.sciencedirect.com/science/article/pii/S0946672X19304201). The aluminium adjuvant initiates an inflammatory response in the immediate vicinity of the injection site. Myriad infiltrating cells flood the damaged area and responding to the inflammation take up adjuvant and antigen into their cytoplasm (https://www.nature.com/articles/srep06287) though not necessarily as an adjuvant-antigen complex (https://www.nature.com/articles/s41598-018-20845-9). Adjuvant is transported to lymph glands (https://journals.sagepub.com/doi/10.1177/0300985818809142) and may also be carried in macrophages (https://www.sciencedirect.com/science/article/pii/S0162013419305719) and other histiocytes throughout the body including into the brain (https://www.sciencedirect.com/science/article/pii/S0946672X17308763). The latter, though demonstrated in an animal model (https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-99) remains to be proven in humans. Vaccines that include an aluminium adjuvant are a source of aluminium to the rest of the body and this should be a concern.

This important and up to date information on aluminium adjuvants is missing from a vaccine safety information website hosted by the NHS (https://www.nhs.uk/conditions/vaccinations/why-vaccination-is-safe-and-important/). Perhaps of equal importance is that the information given there is, at best, incorrect.

Example 1. ‘Adjuvants are added to vaccines in very small amounts, which have been shown to be safe.’
There have not been any clinical trials designed and carried out to test the safety of aluminium adjuvants. Not a single clinical safety trial for any vaccine that includes an aluminium adjuvant. Vaccine manufacturers are not obliged to demonstrate the safety of aluminium adjuvants. Indeed vaccine manufacturers invariably use aluminium adjuvants as placebos in vaccine efficacy trials (https://www.sciencedirect.com/science/article/pii/S0264410X11013089?via%3Dihub).

Example 2. ‘There’s no evidence that the levels of aluminium we come across every day increase the risk of conditions like dementia or autism.’
There may not be consensus that aluminium increases the risk of dementia but there is burgeoning scientific evidence that this is the case. Recent research on aluminium in brain tissue in familial Alzheimer’s disease (https://www.sciencedirect.com/science/article/pii/S0946672X16303777) left very little doubt that aluminium, an accepted neurotoxin, contributes towards Alzheimer’s disease (https://content.iospress.com/articles/journal-of-alzheimers-disease-reports/adr170010). The advice given by the NHS is at best incorrect and at worst misinformation. While the evidence linking aluminium with autism remains preliminary the high content of aluminium in brain tissue in autism (https://www.sciencedirect.com/science/article/pii/S0946672X17308763) should not be so easily, perhaps conveniently, discarded.

 Read the rest of the article here.

 


New Study on Alumunium Adjuvants by Shardlow, Mold, Exley

AluminumThe Journal of Inorganic Biochemistry
12 November, 2019

The interaction of aluminium-based adjuvants with THP-1 macrophages in vitro: Implications for cellular survival and systemic translocation.

Emma Shardlow, Matthew Mold, Christopher Exley

Highlights

•Untreated THP-1 macrophages can survive for up to 9 days in vitro.
•After 9 days most cells have de-differentiated to a monocytic phenotype.
•Cells rapidly engulf aluminium particulates as early as 3 h post exposure.
•Most cells are not adversely impacted by intracellular aluminium adjuvant particles.

Abstract

Within clinical vaccinations, recombinant antigens are routinely entrapped inside or adsorbed onto the surface of aluminium salts in order to increase their immunological potency in vivo. The efficacy of these immunisations is highly dependent upon the recognition and uptake of these complexes by professional phagocytes and their subsequent delivery to the draining lymph nodes for further immunological processing. While monocytes have been shown to internalise aluminium adjuvants and their adsorbates, the role of macrophages in this respect has not been fully established. Furthermore, this study explored the interaction of THP-1 macrophages with aluminium-based adjuvants (ABAs) and how this relationship influenced the survival of such cells in vitro. THP-1 macrophages were exposed to low concentrations of ABAs (1.7 μg/mL Al) for a maximum of seven days. ABA uptake was determined using lumogallion staining and cell viability by both DAPI (4′,6-diamidino-2-phenylindole) staining and LDH (lactate dehydrogenase) assay. Evidence of ABA particle loading was identified within cells at early junctures following treatment and appeared to be quite prolific (>90% cells positive for Al signal after 24 h). Total sample viability (% LDH release) in treated samples was predominantly similar to untreated cells and low levels of cellular death were consistently observed in populations positive for Al uptake. It can thus be concluded that aluminium salts can persist for some time within the intracellular environment of these cells without adversely affecting their viability. These results imply that macrophages may play a role in the systemic translocation of ABAs once administered in the form of an inoculation.  Read more at Science Direct here.


Commentary: As predicted, animal protein containing biologics induce de novo autoimmune disorders

Immune systemBy Vinu Arumugham 

AoA is grateful to Vinu Arumugham who has written an analysis of an article in MedPageToday by Diana Swift ("expert critique" Melinda Engevik): "Biologics Tied to New-Onset IBD and Other Autoimmune Events - Though mechanism is unclear patients need monitoring for de novo disorders". He writes:

They quote: "We don't really understand the mechanism behind this yet, and the effect might apply to agents other than etanercept," Korzenik told the Reading Room

It is absolutely ridiculous for people to claim that the mechanism is “unclear” or not understood. I predicted that animal protein containing biologics would induce de novo autoimmune disorders (1)⁠. Most biologics are produced using Chinese Hamster Ovary (CHO) cells. All biologics thus contain residual CHO host cell proteins. We have described the exact immunological mechanism involved in the induction of autoimmunity by immunization with homologous xenogeneic antigens (2)⁠. Bailey-Kellog et al. developed CHOPPI specifically because induction of autoimmunity by residual host cell proteins is a known problem (3)⁠.

Autoimmune disorders induced by biologics represent the second wave of iatrogenic diseases.

The first wave of iatrogenic diseases are of course all the autoimmune disorders induced by animal protein containing vaccines (1,4–9)⁠. The biologics that are now prescribed to “treat” these vaccine induced disorders are creating their own disaster, exactly as predicted.

For laypersons:

https://www.verywellhealth.com/what-is-an-autoimmune-disease-189661

Says: “You may be wondering how an autoimmune reaction can occur. The autoimmune reaction may be triggered: ... If a foreign substance that is similar to a normal body substance enters the body.

Continue reading "Commentary: As predicted, animal protein containing biologics induce de novo autoimmune disorders" »


SPARK Autism Research And Risk Genes

Dnatoy3Exome sequencing of 457 autism families recruited online provides evidence for autism risk genesExome sequencing of 457 autism families recruited online provides evidence for autism risk genes

We identified variants in genes and loci that are clinically recognized causes or significant contributors to ASD in 10.4% of families without previous genetic findings. In addition, we identified variants that are possibly associated with ASD in an additional 3.4% of families.

What about the other 76.2% of families? Genetics research is fully funded. Biomedical research for autism is shunned. From Autism Speaks to IACC, dollars have gone to the safest haven of research where the fingers can only point straight back to the study participant.


Two New Papers Suggest Rotavirus Vaccines Including Paul Offit's Rotateq Are Undermining Immunity (Abstracts)

Paul offit babyRotavirus Epidemiology and Monovalent Rotavirus Vaccine Effectiveness in Australia: 2010–2017

Julia E. Maguire, Keira Glasgow, Kathryn Glass, Susie Roczo-Farkas, Julie E. Bines, Vicky Sheppeard, Kristine Macartney, Helen E. Quinn

Pediatrics

September 2019

Article

Abstract

BACKGROUND: Rotavirus vaccine has been funded for infants under the Australian National Immunisation Program since 2007, with Rotarix vaccine used in New South Wales, Australia, from that time. In 2017, New South Wales experienced a large outbreak of rotavirus gastroenteritis. We examined epidemiology, genotypic profiles, and vaccine effectiveness (VE) among cases.

METHODS: Laboratory-confirmed cases of rotavirus notified in New South Wales between January 1, 2010 and December 31, 2017 were analyzed. VE was estimated in children via a case-control analysis. Specimens from a sample of hospitalized case patients were genotyped and analyzed.

RESULTS: In 2017, 2319 rotavirus cases were reported, representing a 3.1-fold increase on the 2016 notification rate. The highest rate was among children aged <2 years. For notified cases in 2017, 2-dose VE estimates were 88.4%, 83.7%, and 78.7% in those aged 6 to 11 months, 1 to 3 years, and 4 to 9 years, respectively. VE was significantly reduced from 89.5% within 1 year of vaccination to 77.0% at 5 to 10 years postvaccination. Equinelike G3P[8] (48%) and G8P[8] (23%) were identified as the most common genotypes in case patients aged ≥6 months.

Continue reading "Two New Papers Suggest Rotavirus Vaccines Including Paul Offit's Rotateq Are Undermining Immunity (Abstracts)" »


CORVELVA: 'MRC-5 contained in Priorix Tetra - Complete genome sequencing'

Corvelva vaccingateFrom Corvelva.it

These latest analyses were made possible thanks to the active contribution of the French associations Association Liberté Informations Santé (ALIS), Ligue nationale pour la liberté des vaccinations (LNPLV) and the Australian Association Australian Vaccination-risks Network (AVN), that we thank.

New generation sequencing have become the preferred tool for in-depth analysis in the field of biology and medical science, especially high precision ones.  Thanks to these tools, we can approach in a more modern and comprehensive way a number of applications such as de novo sequencing, metagenomic and epigenomic studies, transcriptome sequencing and genome re-sequencing.

This last one (re-sequencing) is largely used in human field, both for research and diagnostic purposes and consists of NGS - Next Generation Sequencing  of an entire single genome, to map the Single Nucleotide mutations (SNP), insertions and deletions of more or less long sequences that have occurred in certain locations of the genome, and variations in the number of copies of genomic portions/genes (CNV, Copy Number Variants).

This procedure helps to understand the development mechanism of some pathologies, in order to identify the directions for a future clinical treatment as in the case of cancer for example. Indeed, by this method the genetic heritage of a cancer patient can be fully decoded in both normal and cancerous tissue, thus allowing us to comprehend what exactly has changed within the genome, and, if possible, how to intervene with targeted measures.

The  re-sequencing procedure requires that the DNA  of an individual is mechanically broken into small dimension fragments (400-500  base pairs) and artificial DNA parts named adapters are tied to these fragments; adapters make it possible to tie the human DNA  fragments to a glass surface on which the bases reading (A, C, G, T) is performed. The DNA base pairs reading takes place by means of chemical reactions, namely the incorporation of nucleotides that have been marked by fluorescent molecules.  The million sequences (reads) thus obtained are then mapped on the human reference genome by specific software and all the variants are identified comparing the analyzed genome with the reference genome.

This same procedure has been performed on the human genome in Priorix® Tetra lot  n. A71CB256A, genome which belongs to cell line MRC-5 (of fetal origin); the work has been carried out by a company in the USA, that routinely deals with human genome re-sequencing analysis. *

*the name of the laboratory that has performed the analysis will be included in the next formal complaint we will file at the Public Prosecutor of Rome and as well at the Italian and European regulatory bodies. The associations who are filing the analysis funded by Corvelva will be promptly kept up to date with these shocking results too.  We are no denying that we feel, especially as parents, distressed by these results we are reporting - as if what we have found out so far was not enough to worry about.

Results

Continue reading "CORVELVA: 'MRC-5 contained in Priorix Tetra - Complete genome sequencing'" »


Two Recent Papers by Vinu Arumugham

Science post imageAutoepitopes (22 of 27) in rheumatoid arthritis differ from vaccine antigens by a single amino acid residue, ideal for low affinity self reactive T cell mediated autoimmunity and aluminum adjuvant promotes citrullination of vaccine antigens thus the synthesis of ACPA

Arumugham, Vinu

Rheumatoid arthritis (RA) is an autoimmune disorder. Rheumatoid factor (RF) and anti-
citrullinated protein antibodies (ACPA) are known to play a role in RA. RF and ACPA origin is
considered unknown.

Vaccines contain numerous residual proteins of food, animal, plant, fungal and bacterial origin,
from the manufacturing process. Protein sequence analysis shows that 14 of 14 known RF
autoepitopes differ from vaccine antigens by just one amino acid residue. The immune system’s cancer surveillance system looks for exactly such antigens. Cancer begins with a single DNA mutation where one base-pair is modified. Proteins encoded by this DNA segment will therefore also exhibit a single amino acid change. So such peptides with a single amino acid change (neoantigens) are strong markers for cancer and result in an anti-cancer immune
response, when accompanied by innate immune system co-stimulation. With thousands of such proteins in vaccines, there is an overwhelming anti-cancer immune response following vaccine administration. The adjuvant or live virus in the vaccine provides the requisite innate immune system co-stimulation. Since cancer cells/proteins are very similar to normal cells/proteins, attacking cancer always carries the risk of autoimmunity (collateral damage). Therefore vaccines cause numerous autoimmune diseases by triggering unnecessary anti-cancer immune responses.

Continue reading "Two Recent Papers by Vinu Arumugham" »


Rubella Virus Infection, the Congenital Rubella Syndrome, and the Link to Autism

Journal ERPHRubella Virus Infection, the Congenital Rubella Syndrome, and the Link to Autism Read the full pdf here

Anthony R. Mawson 1,* and Ashley M. Croft 2

1 Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences,
Jackson State University, Jackson, MS 39213, USA

2 School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK;
ashley.croft@myport.ac.uk

* Correspondence: amawsn@gmail.com

Received: 15 August 2019; Accepted: 15 September 2019; Published: 22 September 2019

Abstract: Rubella is a systemic virus infection that is usually mild. It can, however, cause severe birth defects known as the congenital rubella syndrome (CRS) when infection occurs early in pregnancy. As many as 8%–13% of children with CRS developed autism during the rubella epidemic of the 1960s compared to the background rate of about 1 new case per 5000 children. Rubella infection and CRS are now rare in the U.S. and in Europe due to widespread vaccination. However, autism rates have risen dramatically in recent decades to about 3% of children today, with many cases appearing after a period of normal development (‘regressive autism’). Evidence is reviewed here suggesting that the signs and symptoms of rubella may be due to alterations in the hepatic metabolism of vitamin A (retinoids), precipitated by the acute phase of the infection. The infection causes mild liver dysfunction and the spillage of stored vitamin A compounds into the circulation, resulting in an endogenous form of hypervitaminosis A. Given that vitamin A is a known teratogen, it is suggested that rubella infection occurring in the early weeks of pregnancy causes CRS through maternal liver dysfunction and exposure of the developing fetus to excessive vitamin A. On this view, the multiple manifestations of CRS and associated autism represent endogenous forms of hypervitaminosis A. It is further proposed that regressive autism results primarily from post-natal influences of a liver-damaging nature and exposure to excess vitamin A, inducing CRS-like features as a function of vitamin A toxicity, but without the associated dysmorphogenesis. A number of environmental factors are discussed that may plausibly be candidates for this role, and suggestions are ordered for testing the model. The model also suggests a number of measures that may be effective both in reducing the risk of fetal CRS in women who acquire rubella in their first trimester and in reversing or minimizing regressive autism among children in whom the diagnosis is suspected or confirmed.